Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Danish Cancer Society Annual Report 2012 Danish Cancer Society | Annual Report 2012 In 2012, 14-year-old Maria Eriksen from Northern Jutland lost her father to cancer. Maria does not attend a grief-therapy group, but has received family counselling at the Danish Cancer Society in Aalborg together with her brother, Daniel, and her mother, Hanne Eriksen. Maria Eriksen is pictured at the Copenhagen Opera House – waiting to present HRH Crown Princess Mary with a bouquet of flowers on the occasion of World Cancer Day. 2 Vision and Goals The Danish Cancer Society’s vision is a life without cancer This vision is realised by • preventing the occurrence of cancer; • offering the possibility of a cure; • helping those afflicted. With its widespread popular support and with the expertise and skills achieved through research, patient support, prevention and information activities, the Danish Cancer Society aims to: • monitor and safeguard patient rights; • identify problems and obstacles; • offer professional and political advice; • define goals and possible solutions; • promote and lead the developments and activities required to reach these goals; • involve relevant parties; • monitor and record results. The Danish Cancer Society works to improve the situation of cancer patients and optimise every aspect of the cancer pathway. The cancer pathway includes all initiatives and offers: from research and prevention, through therapy and care, to rehabilitation and palliation. This goal applies to the Danish Cancer Society’s own activities as well as the efforts for which the public sector is responsible. 3 Icy dip Niels Jessen of Farum was diagnosed with head and neck cancer ten years ago. The treatment devastated him, and he still suffers from the same sequelae as when he completed his treatment, such as disabling fatigue. “I’m not sure if an icy dip relieves my fatigue, but it sure cures winter depression,” he says. Niels Jessen is chairman of the Network for patients with cancer of the throat and oral cavity. Contents Management’s Report Cancer Research Prevention Patient Support Achievements in 2012 Focal Points in 2013 Finances Organisation, Management and Committees Research Grants Patients’ Associations Cancer Counselling Centres Organisation Editors: Kurt Damsgaard (editor-in-chief), communications manager Jytte Dreier, editor Design: Dorte Kayser, Datagraf Communications Printed by: Datagraf Communications Translation: ad Astra Translatører Photos: Tomas Bertelsen ISSN: 0903-6504 4 6 8 20 26 32 34 36 66 68 80 81 83 Danish Cancer Society | Annual Report 2012 Foreword RESEARCH PAVES THE WAY In 2012, the Danish Cancer Society’s research was once again rated at the top of the world’s elite. The Danish Cancer Society Research Center is ranked an undisputed number 1 in the Nordic region and number 22 in Europe out of more than 3,000 of the world’s leading universities and research institutions. We are proud of this - and of the great results from research projects supported by the Danish Cancer Society at a number of hospitals and universities. But we do not intend to rest on our laurels. We are continuously striving to become even better at conducting trail-blazing research which may be quickly deployed for the benefit of cancer patients. A major challenge in our research remains to identify the causes of cancer, which will allow us to conduct research into improved and increasingly precise therapies while at the same time becoming far better at preventing cancer. Living spaces The Danish Cancer Society steps in when cancer patients and their relatives feel that the system lets them down. And we step in when people need help and support. For more than 25 years, the Danish Cancer Society has offered free support and counselling to everyone experiencing cancer close up. We will, of course, continue to do this. But we want to be able to help far more cancer patients, relatives and the bereaved. Consequently, in collaboration with Realdania we are building seven new cancer counselling centres. We call them ‘living spaces’ (“Livsrum”). The counselling centres will be built in close proximity to the oncology wards in Aalborg, Herning, Vejle, Odense, Roskilde, Næstved and Herlev, which provides cancer patients with easy access to see a counsellor, meet with other people in the same situation, take part in activities or simply relax over a cup of coffee before the next hospital examination. There will be a wide range of offers for users at each of the cancer counselling centres – offers which have been and will be developed according to users needs and desires. A responsible healthcare system The new cancer counselling centres cannot accomplish the task alone. There is consequently a great need for the help and support provided to cancer patients and relatives by volunteers in the local units. Among the offers in high demand is a café for cancer patients in conjunction with a municipal training programme. Our goal is that cancer should not be fatal but a disease you can live with. Leif Vestergaard Pedersen, managing director One of our primary challenges is to make sure that we have a responsible healthcare system where cancer patients and their relatives get involved in their own cancer pathway. We also strive to achieve quality at the highest international level throughout the cancer pathway – from early diagnosis and treatment to counselling, rehabilitation or palliative treatment for incurable patients. In addition, we contribute knowledge and research to the healthcare system. The Annual Report gives you a glimpse of what the Danish Cancer Society has been working on in 2012, and outlines what we will do in 2013. Enjoy your reading! Changing norms and culture “Yes to a ban on smoking during working hours”, “Turn down the sun” and “The Smoking Act should also apply to e-cigarettes.” At the Danish Cancer Society, we attack the root of the problem and say what others are afraid to say. We must try to influence the norms and culture in society around us whenever there is scientific evidence to do so. This is our duty. A new focus area, which is sure to cause controversy among the Danish population, is Youths & Alcohol. We need to change the drinking culture and habits of young people. One way of doing this is by means of a campaign which will be launched in the course of 2013. If you scan the QR code below, you can see a film with Leif Vestergaard Pedersen, managing director, talking about the Society’s work (in Danish). What to do: •D ownload and install a free app (such as Scanlife) on your smartphone and scan the code. •O r send a text message with the word ’scan’ to 1220. Follow the instructions and scan the code. Please note that when using 2D codes and sending text messages, your carrier’s standard messaging and data charges apply and are charged via your phone bill. 5 Danish Cancer Society | Annual Report 2012 MANAGEMENT’S REPORT 4,400 cancer patients participated in the Danish Cancer Society’s nationwide survey in 2012, which focused on cancer patients’ needs and experiences during and after treatment. The overall result of the survey is that, fortunately, quite a lot of patients lead a good life after the completion of cancer treatment. However, many people find it difficult to regain their footing, and they lack information and support from their municipalities and general practitioners to help them adjust to their new everyday life. The survey showed that one in five had been admitted through the emergency ward during their treatment pathway, and one in four experienced complications relating to surgery. The survey has further revealed that almost half of the participants needed help to handle physical problems, but that only one-third received the necessary support. Forty-five percent needed help to deal with emotional problems. Also when it comes to the need for home nursing care and domestic help, many respondents feel that the municipality fails to live up to its responsibility. The survey, which is part of a recurring nationwide charting of the current situation for cancer patients, was launched by the Danish Cancer Society’s Central Board. Its results provide valuable knowledge to the Danish Cancer Society and will subsequently contribute to the continued effort to give Danish cancer patients a feeling of consistency and supreme quality during the entire cancer pathway. Acute cancer The Danish Cancer Society has long desired that the Danish regions would report waiting times for all cancer 6 patients. Therefore, we are very pleased that, as of February 2012, it became mandatory for the regions to report waiting times for cancer packages. The figures will be published for the first time in May 2013. The Danish Cancer Society is keeping an eye on this, and will have extra focus on ensuring that cancer patients are in fact treated on time. Throughout the coming year, the Danish Cancer Society will focus particularly on the waiting time until making the diagnosis and on the waiting time for examinations that are initiated before starting the cancer therapy. Act on Smoke-Free Environments One of the main objectives of the Danish Cancer Society is to prevent Danes from taking up smoking, as smoking is the most frequent cause of cancer. The most recent amendment of the Act on Smoke-Free Environments bans smoking at primary and secondary schools and other institutions for young people below the age of 18. At Danish workplaces, smoking is no longer allowed in individual offices. Unfortunately, however, it is still allowed in smoking cubicles.The Danish Cancer Society continues its fight to ensure clean air for all. Vaccination against cervical cancer The Danish Cancer Society is working decisively to achieve the highest vaccination rate in the world, and in 2012, access to vaccination was backed by a large campaign, ‘Wonder Life Friends’ (“Veninder for Vidunderlivet”), which encourages all Danish women born between 1985 and 1992 to accept the offer of free vaccination, which expires at the end of 2013. The Danish Cancer Society expects that the campaign will help to reduce the number of deaths caused by cervical cancer and reduce the number of conisations once the full effect of the vaccine kicks in. Women are accepting the free vaccine offer. At the end of 2012, 56% of the target group had been vaccinated. Before the vaccine was offered for free, this figure was approx. 17%. The ‘Beat Cancer’ campaign In 2012, the Danish Cancer Society launched a new 'Beat Cancer' fundraising campaign on TV2 in week 43. The campaign raised an astounding DKK 100 million for the Danish Cancer Society. With this kind of support from the people of Denmark, the Danish Cancer Society hopes that the 2013 campaign will be an even greater success. And the goal is to reach even more Danes. The funds raised during the campaign will be used for purposes such as conducting research into early diagnosis and improved diagnostics, research into rehabilitation for cancer patients during and after treatment and supporting a rewarding life after cancer, as well as a colon-cancer information campaign. Dallund Rehabilitation Centre For many years, the Danish Cancer Society has promoted the inclusion of Dallund Rehabilitation Centre in the Danish Finance and Appropriation Act. And from 2013, our efforts will bear fruit. The Dallund Rehabilitation Centre is now part of a new research and development centre based in the Region of Southern Denmark. The ‘new’ centre will consist of an R&D department and a communications and documentation department. The centre will continue to conduct research which is aimed at providing knowledge about and increasing rehabilitation offers for the more than 230,000 Danes living with cancer. Maximum duration of sickness benefits Some cancer-afflicted sickness benefit recipients are not covered by any of the current options for extending the sickness benefit period, which means they lose their basic income in the midst of a therapy whose outcome is uncertain. The Danish Cancer Society is therefore working intensively on promoting a so-called ‘eighth extension rule’ which provides for an indefinite extension of the sickness benefit period for the most severely ill patients. Voluntary work In October 2012, the volunteer portal, frivillig.dk, was launched, marking a decisive step in efforts to strengthen voluntary work for the Danish Cancer Society. We hope that the portal will make it easier and more rewarding to be a volunteer. Volunteers seem to have embraced the new site in any case. Almost 900 people created a profile during the first two months. Frivillig. dk is extremely important because voluntary work is an essential prerequisite for much of the funding of the Danish Cancer Society’s work. The Society In 2012, the Committee of Representatives decided to revise the Danish Cancer Society’s Articles of Association. Local units and regional committees contributed proposals and comments. The revision of the Articles of Association must be finished in 2014 and presented to the Committee of Representatives for approval. 2012 was also the year when the management launched a major project of formulating new goals to replace the 2015 goals. Based on the Danish Cancer Society’s foundation, five strategic goals for the cancer cause and the Society’s work towards 2020 are being developed. 7 Danish Cancer Society | Annual Report 2012 The Danish Cancer Society has built up a large, unique biobank containing samples of blood, urine and fat tissue from more than 57,000 Danish men and women. The large biobank is valuable to people like Anja Olsen, senior researcher from the Danish Cancer Society Research Center, who conducts research into correlations between dietary habits, lifestyle and cancer. 8 cancer research The world-class research produced by the Danish Cancer Society needs to be maintained and further developed. The Society spends approx. DKK 250 million on research every year. Research grants from the Danish Cancer Society 2002 – 2012 DKK million 300 250 200 150 100 50 0 2002 2004 2006 2008 2010 2012 9 Danish Cancer Society | Annual Report 2012 THE DANISH CANCER SOCIETY RESEARCH CENTer Almost half of the funding received by the Danish Cancer Society is used for research. This research aims to pave the way for reducing the cancer rate, increasing the survival rate and ensuring that survivors lead more rewarding lives after cancer. The Danish Cancer Society conducts its own research and at the same time supports cancer research at hospitals and universities throughout Denmark. On 1 January 2012, all researchers were gathered under one umbrella at the Danish Cancer Society Research Center. This merger of biological and epidemiological research aims to improve the collaboration between these two different research areas. New knowledge from biological research may be applied by epidemiologists to generate new results – and vice versa. This implies an important organisational change towards fewer but larger research groups to provide better prospects for researchers to collaborate more closely across research disciplines. The goal is: • to procure new knowledge about the causes of cancer, thus making prevention of cancer more efficient; • t o develop examination techniques for early detection to ensure that the disease is identified at a curable stage; • t o find gentler alternatives to chemotherapy and radiation therapy for patients who still require intensive cancer treatment; and • t o measure the scope of harmful long-term sequelae of cancer treatment on patients’ physical and mental health, so that such effects can be prevented, treated or relieved in the future. 10 In four out of ten cases of cancer, the cause is known, and these causes include tobacco, sunlight, alcohol, radioactive radiation and HPV infection. In order to become better at preventing cancer, however, a targeted research effort is required. Even though treatment has improved in recent decades, many patients still die from cancer. The Danish Cancer Society Research Center works to develop methods which can predict the effect of a treatment on individual patients, thus enabling doctors to choose the ‘right treatment for the right patient at the right time’. In addition, the researchers focus on mental and social conditions and how these affect how patients cope with cancer. The research carried out at the Centre also ensures that the Danish Cancer Society’s scientific decisions and recommendations for politicians, healthcare professionals and cancer patients are always in line with the latest knowledge. In 2012, the Centre employed more than 160 researchers and specialists representing 20 nationalities, and attracted 60 international visiting researchers. Eight years of world-class research Since 2004, the Danish Cancer Society’s research organisation has been rated among the best in the world. In 2012 the Danish Cancer Society was once again ranked as the undisputed best institution in the Nordic region and 22nd in Europe by the international Scimago Institutions Rankings, which annually ranks the best research institutions in the world. Scimago evaluated more than 3,000 research institutions and universities, and the research conducted by the Danish Cancer Society was consistently among the top 100 in the world. The Top 10 of Research “Over the last eight years, our cancer research has succeeded in maintaining a top position in the international ranking of research, which, in the world of research, is considered the ‘international scorecard for good research’. Yet even though our research scores high, we still strive to become even better at generating new results to benefit patients,” says Jørgen H. Olsen, Head of Research. Cancer Research TREATMENT OF METASTASISED CANCER One of the most dangerous characteristics of cancer is the possibility of cells metastasising from the original tumour. In 2012, the Danish Cancer Society presented new knowledge about a protein which is crucial for the metastasisation of cancer cells. At the same time the researchers developed an antibody against the protein, and animal studies show that it is extremely effective at inhibiting metastasis. The protein behind these remarkable results is called S100A4. Previous research has shown that the protein is an important factor in the development and spread of cancer. However, in 2012 researchers from the Danish Cancer Society, among others, showed that S100A4 is upregulated in connection with brain damage. This helps to protect the nerve cells and allows for faster healing of the tissue. And the fact that S100A4 plays a role in wound healing is interesting because there are many similarities between cancer and wounds that will not heal. “The results are very interesting. Now we know that the way in which S100A4 stimulates growth and metastasis is by keeping the wound-like processes going,” explains Noona Ambartsumian, senior researcher and one of the persons behind the discovery. be the first treatment with the ability to block metastasis,” Noona Ambartsumian says. The researchers have patented the antibody and are now in the process of finding partners and soliciting financial support to develop a therapy based on the antibody. So far, the results are a very encouraging example of how basic research can be successfully converted into preclinical cancer treatment. And, if successful, it can save many lives. “Previous research has shown that S100A4 is upregulated in many types of cancer, such as breast, lung, colon, pancreatic, prostate, etc. Thus, efficient treatment will be a huge breakthrough in the fight against cancer,” Noona Ambartsumian says. Behind the research in S100A4 The group behind the new results comprises Professor Eugene Lukanidin, senior researcher Mariam Grigorian, senior researcher Noona Ambartsumian, and Jörg Klingelhöfer, PhD, in close collaboration with researchers from the University of Copenhagen. In 2012, the researchers moved from the Danish Cancer Society to the University of Copenhagen where they set up a team specialising in neurooncology with support from the Danish Cancer Society. For many years, the research team has been studying the specific role of S100A4 in cancer, and they have shown, among other things, that it is the cancer cells themselves which stimulate surrounding cells to excrete S100A4. This probably takes place at a very early stage of the disease and enables cancer cells to move and metastasise in other parts of the body. At the same time, S100A4 stimulates the increased formation of blood vessels supplying oxygen and nourishment to the growing cancer cells. The photos show experiments with growing cell cultures in the lab. Towards the first treatment While showing that S100A4 is a key factor in preventing metastasis, the research team also developed an antibody to block S100A4. The researchers have tested the antibody in mice experiments and the successful outcome was published in the scientific journal Neoplasia at the end of the year. “The antibody efficiently inhibits the metastasis of cancer in mice. These results are extremely encouraging and make us hopeful that we will be able to develop a treatment which can be used on humans. If we succeed, it will The cells grow in a special gel in which they can spread and mimic the processes that are involved in metastasis in the body. The radiating arms from cell mass are offshoots that show the cells spreading in the gel around them. S100A4 has been added to these cells. This makes the cells more invasive. They form more offshoots which grow into the surrounding gel. Here, antibodies against S100A4 have been added, which inhibits the spreading of the cells. 11 Danish Cancer Society | Annual Report 2012 KEY TO UNDERSTANDING BRAIN CANCER Researchers from the Danish Cancer Society have made a discovery which may increase our knowledge and understanding of how malignant brain tumours develop. The discovery is considered essential knowledge in endeavours to improve the treatment of glioblastoma – an aggressive type of brain tumour. Together with senior researcher Petra Hamerlik, professor Jiri Bartek discovered the link between stem cells from the glioblastoma tumour and the VEGFR2 protein, whose function is to help the cancer cells create new blood vessels. These blood vessels are essential in supplying the tumour with nourishment which allows it to survive and spread. The researchers discovered that the stem cells have an ‘autonomous’ signalling mechanism which enables the cells to produce both VEGF and VEGFR2, a receptor protein attached to the cell wall which can respond to signals from VEGF. The mechanism functions like a key for a lock. When the key (the VEGF protein) is inserted into the lock (the VEGFR receptor) of the stem cells, the cells receive a signal which helps them to protect themselves and develop resistance to anti-VEGF medicine. This signalling mechanism also protects stem cells more efficiently against radiation therapy. “This new understanding of the interaction between stem cells and the VEGFR2 protein supports long-term hopes of designing a more efficient treatment which could block signals from the VEGF protein and make cancer cells more susceptible to treatment,” says Petra Hamerlik. 12 Brain cancer Glioblastoma tumours are the most common type of brain cancer in adults. Glioblastoma is also one of the most aggressive types of cancer, characterised by rapidly growing tumours and spreading of cancer cells. The treatment, which is a combination of radiation therapy and chemotherapy, has not yielded good results so far. In aggregate, 1,200 new cases of brain tumours are detected annually, and the number has been increasing every year. Today, more than 10,000 Danes are living with the disease. Basis for more efficient treatment For some years, researchers have been aware that there had to be some form of communication between the stem cells and the VEGF protein. Based on this assumption, the researchers have tried out a new treatment strategy of injecting a special antibody which should block the VEGF protein, and thus keep the tumour from growing. The treatment was a success. Unfortunately, however, the antibodies were only effective for a short period of time until the glioblastoma itself developed new resistance to the antibodies after which it could continue to grow and spread. With the discovery of the actual communication mechanism between the glioblastoma stem cells and the VEGFR2 protein, researchers at the Danish Cancer Society, in collaboration with Rigshospitalet and researchers in the US, have provided doctors with a basis for developing a more efficient treatment in the coming years, and hopefully also for improving survival rates. The new knowledge about the signalling mechanism and the glioblastoma was published in the prestigious American Journal of Experimental Medicine. Scan and learn more If you scan the QR code below, you can see an interview with senior researcher Petra Hamerlik. What to do • Download and install a free app (e.g. Scanlife) on your smartphone and scan the code. • Or send a text message with the word ‘scan’ to 1220. Follow the instructions and scan the code. Please note that when using 2D codes and sending text messages your carrier’s standard messaging and data charges apply and are paid via your phone bill. Cancer Research VEGF secretion VEGFR2 expression in GSC n io Irradiat VEG F se stra t ion i R2 GF VE n tio Angiogenesis GSC survival VEGF VEGF VEGFR2 homodimer VEGFR2/NRP-1 heterodimer GSC: glioma stem-like cell EC: endothelial cell CT: chemotherapy Tumour relapse? IR/CT ibi nh Immunofluorescence staining of VEGFR2 and NRP in a glioblastoma (primary glioblastoma multiforme). Green is VEGFR, purple is NRP1 and blue are nuclei. que VEGF sequ estra R2 in hibit tion ion Tumour reduction IR/CT Angiogenesis GSC survival Illustration of VEGFR2/NRP-1 signalling and its function in Glioma Stem-like Cells (GSCs). (A) Ionising radiation enhances the amount of VEGFR2 and stimulates pro-survival signalling in the cell. (B) For a period, the substance Bevacizumab inhibits vascularisation. (C) Repeated series of VEGFR2-inhibiting treatment block signalling in the cell. The tumour shrinks when followed up by radiation and chemotherapy. 13 Danish Cancer Society | Annual Report 2012 DISPARITY AND CANCER In 2012, the research unit ‘Life after cancer’ revealed new knowledge about social disparity and cancer survival. Studies of three major types of cancer have shown that social position in particular affects how advanced the disease is when it is diagnosed. Researchers at the Danish Cancer Society have previously shown that socioeconomic conditions have an impact on several aspects related to cancer, irrespective of type. Such conditions influence the type of cancer that develops as well as the prospects of surviving it. Research also shows that the prospects of surviving cancer improve proportonally with the level of education and the level of income, and that the survival rate is higher for cohabitants than for individuals who live alone. In 2012, the researchers published the results of a more detailed study of three types of cancer: lung cancer, lymphoma and cervical cancer. By investigating a number of circumstances relating to each of the diseases, the aim was to describe the reasons behind the social disparity in cancer survival. One of the areas studied was the stage of the disease at the time of detection. Furthermore, the researchers studied whether treatment had been correct and optimal. And finally, they examined the importance of comorbidity, i.e. whether the patients had other disorders or diseases when they were diagnosed with cancer. 14 Social disparity related to stage at detection Eye-opener for healthcare professionals Generally speaking, lung cancer, lymphoma and cervical cancer were at different stages at the time of detection. The disease was detected at a more advanced stage in patients with a short-cycle education and a low income level and living alone. The current results show that it would be extremely beneficial to strive to ensure, for instance, that cancer is detected as early as possible in all patients, and that people who live alone and need to keep track of all their agreements and doctor consultations on their own also receive the best possible treatment. This effort could be carried out through protocols, cancer plans, etc. The results furthermore showed that non-small cell lung cancer patients who had low income and status as singles were more likely to undergo surgery than those who earned more and were living in a relationship. The same applied to patients with non-Hodgkin’s lymphoma, where there was social and economic disparity in terms of who received radiotherapy. However, with respect to the importance of having one or more disorders or diseases at the time of the cancer diagnosis, this turned out to depend on the type of disease being studied. “Comorbidity does not affect patients with lung cancer. But it does have an impact on women with cervical cancer and can cause the diagnosis to be made later,” says senior researcher Susanne Dalton. Susanne Dalton believes that the current results ought to be an eye-opener for healthcare professionals in their interaction with patients. “The results reveal a clear pattern for patients with a certain profile. A number of reasons could explain why these particular factors make patients more vulnerable, and we are not familiar with all of them yet. But the knowledge we possess should sound an alarm for doctors, nurses, and other healthcare professionals in their dealings with patients with little education, a low income or who live alone. They require special attention to make sure they receive the same provision of care and an equally high level of treatment as patients with more resourceful profiles,” Susanne Dalton says. Cancer Research PROBLEMATIC TEST OF PROSTATE CANCER The number of men who get prostate cancer, has tripled in only 15 years. Today, the disease is detected much earlier thanks to increased use of so-called PSA tests. At the same time, however, a survey from the Danish Cancer Society has shown that this does not affect the mortality rate, even though the disease is generally detected and treated earlier. In collaboration with urologists from Rigshospitalet in Copenhagen, the Danish Cancer Society has followed all prostate cancer patients – almost 63,000 men – listed in the national Cancer Registry from 1978 to 2009. “It is true that – despite increased focus on prostate cancer, more frequent PSA testing, earlier treatment and more treatment options – we have yet to observe any effect on the disease’s mortality rate,” says Søren Friis, senior researcher and doctor. Prostate cancer is the most frequent type of cancer in Danish males and the second-highest cause of death. Approx. 1,200 men die of prostate cancer every year. A long life without symptoms The survey suggests that the increased use of PSA testing over the past 15 years is not always an advantage for the individual male – or for the health economy. Many elderly men can live a long life with undiagnosed prostate cancer which develops only slowly and does not lead to any symptoms. The problem is that it is difficult to distinguish between those who should be offered treatment quickly, and those who may benefit from not being treated, and are monitored over time instead - something which would also benefit the healthcare system. Over-treatment without effect “The increased use of PSA testing means that prostate cancer is often discovered at an early stage of the disease. Once diagnosed, many patients expect treatment, even if it often has serious side-effects and may not even be necessary since most cases of prostate cancer develop slowly,” explains Søren Friis. Most frequent type of cancer for men Søren Friis fears that patients are being overtreated. In addition, the PSA test is not very reliable. There are many false positives, and also a certain amount of false-negative results. “It is unlikely that this is explained by an actual increase in the prevalence of the disease. The common use of PSA (prostate-specific antigen) testing seems to be the primary reason that three times as many cases of prostate cancer are diagnosed today,” Søren Friis says. False positives of course trigger a fear in men who are actually healthy. Often this patient will still have to go through a lengthy process of additional examinations and controls before the prostate cancer diagnosis can be ruled out. When should PSA testing be performed? A previous study showed that eight out of ten 80-year-old males with prostate cancer died from diseases other than prostate cancer, such as cardiovascular disease or diabetes. Consequently, it is recommended that the PSA test only be used if a medical assessment justifies this, or if two or more close relatives have suffered from the disease. Treatment of prostate cancer Not all types of prostate cancer require treatment. For up to 50% of men diagnosed with prostate cancer, the disease is not immediately life-threatening. Men diagnosed with non-aggressive prostate cancer at an advanced age should not undergo treatment. Instead the doctor should follow the patient over time. The treatment of prostate cancer often has serious side effects, such as impotence and incontinence. The treatment primarily consists of surgery, radiation therapy or anti-hormone therapy. In recent years, a number of new treatments have been developed, such as new forms of chemotherapy and so-called prostate cancer vaccines (immunotherapy) which seem to prolong the survival rate. 15 Danish Cancer Society | Annual Report 2012 “But the PSA test should never be used without thorough consideration, and general screening should be avoided. The primary purpose of a screening test is to reduce the mortality rate and improve the quality of life – not to provoke illness, create unnecessary fear or overtreatment. False-negative results are also problematic because they can create a false sense of security in patient and doctor alike, as the doctor thinks the patient is healthy. Consequently, the patient will not be monitored closely enough by the doctor. How should PSA testing be used? The results were published in the journal Acta Oncologica in 2012. “The PSA test is a good tool for doctors to make the diagnosis, provided, however, that there are symptoms or examinations indicating a possible prostate cancer diagnosis. As a screening tool, the indication for using PSA testing is currently reserved for men with a hereditary predisposition. The PSA test is also a very valuable tool for doctors’ monitoring of patients, both those who have been treated for the disease and those who are just being monitored over time,” Søren Friis says, adding: Prevalence and mortality of prostate cancer 80 Prevalence and mortality of prostate cancer 80 60 20 40 0 19781982 20 1983- 19881987 1992 1993- 19981997 2002 Prevalence Mortality 0 19781982 1983- 19881987 1992 1993- 19981997 2002 Prevalence Mortality Age-adjusted number of prostate cancer cases 16 per 100,000 person-years 2003- 20082007 2009 Diet, genes and environment •Documented correlation between low levels of vitamin D and an unhealthy lifestyle. •The most comprehensive survey so far charting the Danes’ vitamin D status has been launched. •New collaboration has been set up to investigate whether lignans, a plant substance, is an effective weapon in the fight against cancer. FOCAL POINTS IN 2013 The primary goal of the Danish Cancer Society Research Center is to ensure that its research continues to be ranked among the international elite. This means that the Center should continue to deliver research results which can create value for Danish cancer patients and for cancer treatment on a global scale. 40 60 RESULTS IN 2012 Age-adjusted number of prostate cancer cases per 100,000 person-years 2003- 20082007 2009 The merger of the former research departments to form the new Danish Cancer Society Research Center has been carried out as planned, but work is still in progress to make the final pieces fall into place before the new organisation is complete. 2013 will mark the year where we take the last steps by forming two new research groups. So far, the Center consists of five research units: Cancer Research Statistics, bioinformatics and registers Life after cancer Cell death and metabolism •Use of PSA testing to screen for prostate cancer is problematic as the test is unable to differentiate between whether the disease will develop slowly and without symptoms or when treatment should be offered quickly. •Social disparity in survival rates after cervical cancer as well non-Hodgkin's lymphoma. •Breakthrough for research into aggressive breast cancer. The researchers have identified part of the network which causes breast cancer to metastasise •New knowledge about breast cancer which is resistant to anti-hormone therapy. Researchers have now found an explanation of how cancer cells avoid the ‘death signals’ activated during anti-hormone therapy. Virus, lifestyle and genes •Substantial decline in the occurrence of genital warts after the introduction of the HPV vaccine. Diet, genes and environment •Identify environmental factors (particularly traffic pollution), work environment and lifestyles which increase the risk of cancer and weaken the prognosis for cancer patients •Assess the impact of diet on the risk of cancer •Identify genetic risk factors related to cancer •Develop non-invasive methods for early detection of cancer Virus, lifestyle and genes •New screening methods including HPV against cervical cancer •Monitor the effect of HPV vaccine in the Danish population •Assess the risk of cancer in children born to women who had received fertility treatment Genome integrity • New key to understanding fatal brain cancer •Biomarkers in connection with replication stress and their relevance to cancer •Early detection of cancer in female genitalia and the breast •Genetic-environmental interaction: impact on the development of ovarian and breast cancer •Identify factors which may affect the course of the disease in women with ovarian cancer Cell death and metabolism •Describe the cell’s signalling systems relevant to cancer development •Assess the role of cell membranes in cancer development •Chart the mechanisms associated with cellular stress and cancer development •Describe the molecular mechanisms which are central to the development of treatment resistance in breast cancer •Find biomarkers for the development of resistance to anti-estrogens Genome integrity •Identify unknown, but vital mechanisms in the cancer cell which can be used in targeted treatment of cancer •Chart which mechanisms keep the genome (the cell’s hereditary material) intact despite genotoxic stress •Epigenetic processes in cancer: Structure and function of elements in the cell core •Studies of the role of proteins in cancer development Life after cancer •Quality-of-life surveys among cancer patients •Health consequences of cancer treatment in children and young people •Post-treatment health-impairment sequelae in adult cancer survivors •Research into how to support patients and relatives •Create a coherent interdepartmental and intersector cancer rehabilitation pathway in the healthcare system 17 Danish Cancer Society | Annual Report 2012 EXTERNAL RESEARCH Research into advanced imaging diagnostics Ultrasound is one of the primary tools for offering individually designed therapy to patients with upper gastrointestinal cancer. Michael Bau Mortensen, consultant doctor, PhD, has been employed at the University of Southern Denmark in a professorship created by the Danish Cancer Society. He will be conducting research into the potential of advanced imaging diagnostics for helping patients who incur a life-threatening disease. Figure 1. Relapse of cancer in the small pelvis. The tumour (T) is found by ultrasonic identification through a 12 mm port in the patient’s stomach (laparoscopy). Photo: Michael Bau Mortensen Every year, more than 2,300 Danes are afflicted by cancer in the oesophagus, stomach, pancreas, liver or the biliary passage – referred to collectively as upper gastrointestinal cancer. These are life-threatening diseases, and a prompt and precise diagnosis is crucial. T This is exactly the purpose of the professorship at the University of Southern Denmark, where Michael Bau Mortensen will be conducting research into methods that will enable doctors to make a precise diagnosis at the earliest possible stage of the disease. T T Figure 2. A few cm from the tumour in figure 1, ultrasound was used to identify two additional cancerous tumours (marked T). Photo: Michael Bau Mortensen 18 “The combination of ultrasound examinations using cameras and keyhole surgery gives an image of the disease which is precise enough for us to select the best treatment for the patient with 90% certainty. No other investigation provides the same degree of certainty,” Michael Bau Mortensen says. An accurate diagnosis is crucial for providing the best possible treatment, partly by distinguishing patients who should be offered curative surgery from patients who can only be offered palliative treatment, and partly by tailoring therapies to individual patients and identifying patients who, for instance, should only be offered surgery after receiving chemotherapy or radiation therapy to reduce the tumour. Interdisciplinary centre Apart from imaging diagnostics research, the professor will be responsible for setting up the first centre in Denmark to combine clinical research with basic research in areas such as the molecular biology and genetics of upper gastrointestinal cancer. “We believe in the theory that many cases of upper gastrointestinal cancer which are treated in the same way today in fact represent diseases which are dissimilar from a molecular point of view. Our goal is to identify cancercell markers which may reveal the optimal treatment for the individual patient,” says Michael Bau Mortensen. Michael Bau Mortensen is convinced that the significant research efforts set in motion by the new professorship will benefit the patients. “Fast and precise diagnosis combined with a more detailed categorisation of the patients’ diseases will undoubtedly enable us to offer better and more individualised treatment. And at the end of the day, this will improve the survival rate,” says Michael Bau Mortensen. Cancer Research Tailored post-treatment follow-up for women Every year, some 1,600 women are diagnosed with gynaecological cancer. Women who undergo surgery to treat their cancer disease subsequently enter a threeto-five-year post-treatment follow-up process. Today, the focus of the post-treatment follow-up is primarily on physical examinations to monitor for recurrence. “These women are usually very nervous when they show up for follow-up visits. And even though the physical examination is reassures them, many struggle with problems such as which symptoms to take seriously, fatigue, sexual problems and fertility problems,” according to Mette Linnet Olesen, nurse and PhD student, Rigshospitalet. A new research project aims to find novel ways of intensifying the tailoring of post-treatment follow-up to the needs of the individual woman. A research project involving women with gynaecological cancer aims to ensure that the post-treatment follow-up is tailored to the needs of the individual woman to a much greater extent. The research project is based on an adapted, researchbased patient-focussed method involving the use of reflection sheets and communication. The women are offered two to four conversations, and prior to each conversation, each woman will be sent a number of reflection sheets for completion at home. The sheets will then form the basis of the conversation she will have. “In this way, we get to focus exactly on the challenges and problems she is facing. One of the sheets is diseasespecific and aims to assist the woman in distinguishing between symptoms which are ‘only’ long-term sequelae from her treatment and symptoms which could indicate the recurrence of cancer and to which the woman should react immediately,” says Mette Linnet Olesen, adding: “It remains to be seen whether this will also make women react faster to serious symptoms than is presently the case.” 250 women in randomised study 250 women will be enrolled in the study, which will be randomised. Half will be offered the conversations immediately after their enrolment in the project, and the other half will receive the offer after nine months. Mette Linnet Olesen hopes the conversations will be instrumental in finding women who have special psychosocial challenges which they cannot overcome without help and support. Supplement to medical follow-up The new nurse-based effort should be seen as a supplement to the medical follow-up carried out by doctors. Professor Bent Ottesen, Centre Director at Rigshospitalet, has great expectations of the project. “Our traditional post-treatment follow-up is currently being questioned. We have been largely focussing on detecting recurrence as soon as possible and have been less concerned with the needs of the individual woman. I expect that in the future, we will see the follow-up visits as an interdisciplinary collaboration where the woman participates on an equal footing. Individually designed procedures will provide an optimal follow-up process, both from a professional point of view and in the eyes of the patients,” says Bent Ottesen. The Danish Cancer Society supports the project with DKK 450,000. The project is expected to be completed in two years. 19 prevention The Danish Cancer Society strives to ensure that knowledge about prevention is translated into tangible improvements. With the knowledge available today, one third of all new cancer cases and up to half of all cancer deaths can be avoided. All cancers except other skin cancers Incidence: Number aged 0-18+ 20000 18000 16000 14000 12000 10000 2000 2002 2004 2006 2008 2010 Men Woman 20 Two friends, Amalie Miang and Eva Høj Andersen, in their GP’s waiting room – ready to get vaccinated against HPV. 21 Danish Cancer Society | Annual Report 2012 PREVENTION AND DOCUMENTATION Some 36,000 Danes were diagnosed with cancer in 2012. But this doesn’t have to be the case. Roughly one third of all cancer cases and half of all cancer deaths are preventable if we all followed the recommendations, and if we designed our society in accordance with the knowledge currently available. Fortunately, things are moving in the right direction. In 2012, 120,000 Danes quit smoking, and the number of daily smokers declined from 18% in 2011 to 17% in 2012. Another encouraging development was that the HPV vaccine was made free of charge for many young women in 2012, and that sun protection was included as one of the National Health and Medicines Authority's new prevention packages aimed at assisting the municipalities in prioritising and planning their preventive efforts. The HPV vaccination, smoking and sun protection are also some of the areas of focus of the 64 employees and 30 student assistants in Prevention and Documentation. Other areas include screening, physical activity and diet. A final core area is documentation. Prevalence, mortality and cancer survival rates consti- tute important information when prioritising the efforts and measuring their effects. The work at Prevention and Documentation consists primarily in the collection and dissemination of knowledge, conducting research into behaviour and behavioural changes, as well as practical and political action. Most of the activities are carried out and funded in collaboration with external groups, companies and authorities. The broad approach to these tasks efforts gives the Danish Cancer Society a unique opportunity to play a key role in the prevention of cancer in Denmark. NEW SMOKE-FREE WINDS Today, 39% of all Danes are ex-smokers. This corresponds to no less than 1.8 million people. This figure must be significantly reduced. For this dream to come true, we first of all need to stop young new generations from taking up smoking. The number of Danish smokers has dropped significantly. In December 2012, a survey showed that 22% of the adult Danish population are smokers. In 2000, this number was 33%. Also the attitude towards smoking has changed significantly. Today, the Act on Smoking has become popular, and smoking indoors in a private home is now considered more or less unacceptable. Thus in 2012, 69% said that they do not accept smoking in their homes. In 2011, this number was only 61%. 22 The encouraging statistics derive from two nationwide surveys carried out annually by the Danish Cancer Society in collaboration with the National Health and Medicines Authority, the Danish Heart Foundation and the Danish Lung Association. Reaching the young generations Unfortunately, the same positive developments cannot be observed in younger generations, where the number of smokers in 2010 was roughly the same as in 2006. The latest figures show that 11% of the boys and 10% of the girls in the 9th grade smoke. This explains why young people’s smoking habits have been a focus area at the Danish Cancer Society for years. Our activities include Xhale, an electronic quit-smoking program which sends text messages and emails to youths, encouraging them to stick to their decision to quit smoking. Another effort is the X:IT project, which provides materials and guidelines to schools and municipalities, helping them to keep 7th – 9th graders smoke-free. Fortunately, in 2012 political focus was also directed at preventing smoking among youths. For instance, money has been allocated through the public special pool funds for the social areas, with Xhale and X:IT as important elements. “X:IT is a scientifically based project, drawing partly on lessons learned in Norway, where the number of young smokers has successfully been reduced to 6% through rules, education, collaboration with parents and contracts with pupils. For almost three years, we have been running an experiment based on a similar model at 100 schools. This will now be scaled up,” says project manager Per Kim Nielsen. Another focus area has been the residential continuation schools which have been criticised for years for being an incubator for new smokers. In collaboration with the Danish association of residential continuation schools, Prevention and Documentation has worked to ensure that the majority of the schools now have appropriate smoking policies, and that they offer training and as- prevention Clean air for the lungs In November, the Danish Cancer Society invited volunteers to a workshop about future efforts aimed at giving Danish children a smoke-free upbringing. This resulted in a project called ‘Clean Air for the Lungs’, which will run in 2013. The aim is to ensure that children in a childminder scheme are not exposed to tobacco-contaminated air. As part of the effort, volunteers work locally to influence the municipalities to gradually introduce completely smoke-free childminder homes 24 hours a day. sistance in how to quit smoking. At schools which collaborated with the Danish Cancer Society, the number of smokers has been cut in half. This means that the number of smokers at schools where smoking is prohibited amounted to 11.5%, and at schools where it is allowed, amounted to 20.1% in 2010–2011. New Act on Smoking There was also focus on youths when the Act on Smoking was amended in 2012. As the most important change, the amended act included a total ban on smoking at childcare institutions, primary and secondary schools and continuation schools where most of the pupils are under 18. MORE HPV VACCINES 27 August 2012 was a good and long-awaited day at Prevention and Documentation. From this day onwards, women born between 1985 and 1992 could see their doctor and be vaccinated against HPV free of charge. At the same time, the day marked the launch of a large-scale campaign aimed at encouraging young women to take advantage of this offer. About 70% of all cases of cervical cancer are caused by the types of HPV which the HPV vaccine protects against. Therefore, we hope that this type of cancer can be eliminated entirely in Denmark by means of vaccination and screening. At the Danish Cancer Society, we strive to achieve the highest vaccination rate in the world. The first figures indicate that we are making quick progress. The number of vaccinated women aged 20–27 almost doubled during the very first month in which the vaccine was provided free of charge. This corresponds to 50,000 women who are now far better protected against cervical cancer. This number has grown since then. One of the reasons for this is the campaign ‘Wonder Life Friends’ (“Veninder for Vidunderlivet”) by means of which the Danish Cancer Society attempts to reach the target group via Facebook, cinema commercial spots and popular websites, and encourage the young women to get the three injections together with a friend. Target group reached Unfortunately, the act did not lead to the clampdown at workplaces which the Danish Cancer Society had hoped for. It is no longer allowed to smoke in individual offices, but it is still allowed to set up designated smoking rooms and smoking cubicles at workplaces. An analysis of the campaign shows that the strategy has worked so far. For instance, 87% of the target group remembered at least one element of the campaign, and many more had become aware of the HPV vaccine’s existence. Before the launch of the campaign, only 56% of the target group knew that the vaccine was free. This number had increased to 97% after the campaign. “Already after two months, 80,000 women had already been vaccinated, which is extremely promising. The campaign has also rubbed off on other age groups who want the vaccine even though they have to pay for it themselves. This is very positive, because we want as many women as possible get the vaccine,” says Iben Holten, consultant doctor and project manager. Continued focus on free vaccine In 2013, the Danish Cancer Society will continue its effort to make the HPV vaccine a free and permanent offer for all young women up to and including the age of 26. For women aged 20–27, the offer only runs until the end of 2013, and there is currently no offer for women aged 18-20 who were previously comprised by a catchup programme. Great effort from volunteers Volunteers at the Danish Cancer Society have distributed campaign material to more than 700 general practitioners, and some 30 local units have ordered the campaign material for distribution to the target group. 23 Danish Cancer Society | Annual Report 2012 THE NUMBERS REVEAL THE DEVELOPMENTS Intestinal cancer is sharply increasing: still more patients will need rehabilitation. Region Zealand is now ranked an undesirable first with respect to the number of cases of lung cancer. These are just a few examples of the information available in the NORDCAN cancer statistics database – information which the Danish Cancer Society uses for planning initiatives and taking action. Intestinal cancer is the third most common type of cancer, and every year almost 4,300 Danes are diagnosed with colon or colorectal cancer. This number will increase in the years ahead according to NORDCAN data, a publicly-available database based on Nordic cancer registries for which the Danish Cancer Society functions as secretariat. It is estimated that the incidence of colon and colorectal cancer in Denmark will increase by 67% for men and 56% for women between now and 2030. This estimate can be made because it has been possible, since 2012, to make projections in NORDCAN until the year 2030. Colon and colorectal cancer Incidence: ASR (W), men aged 0-85+ 60 50 40 30 20 10 0 1982 1987 1992 1997 DK, North Denmark Region DK, Central Denmark Region DK, Region of Southern Denmark DK, Capital Region of Denmark DK, Region Zealand 24 2002 2007 “This offers a unique opportunity to predict how many people will be afflicted with cancer in the years to come. This is relevant, for instance, when planning a screening programme for intestinal cancer which has long been a wish at the Danish Cancer Society, and which will be implemented in 2014. It also hints that we need to do more to tell Danes about how to prevent the disease,” according to senior statistician Gerda Engholm. Cancer at regional level In 2012, it became possible to retrieve data at regional level as well. This now enables us to see how many people develop cancer in each region, and we can monitor whether the prevalence, mortality rate and number of Danes living after cancer are declining or increasing. For instance, we can see that the Capital Region no longer has the highest number of lung cancer cases. For both men and women, Region Zealand is ranked first in terms of the incidence of lung cancer. The same applies to intestinal cancer, which, like lung cancer, is highly related to lifestyle. “We can see that in some parts of Denmark, people have done a better job of learning from the message that they should quit smoking, exercise and eat a healthy diet than in other parts of the country. There is considerable social disparity with respect to health, which is also reflected in cancer statistics, both in terms of the number of people who get cancer and how they cope with their disease,” Gerda Engholm says. Consequently, social disparity is also a focus area when Prevention and Documentation plans new campaigns. An example of this is our effort to persuade all young women – regardless of social and geographical background – to take advantage of the free HPV vaccination. Other examples include our efforts to encourage young people with reading difficulties to refrain from taking up smoking. prevention RESULTS IN 2012 • The number of municipalities providing the flexible new quit-smoking programme ‘Come and Quit’ (“Kom & Kvit”) increased from 18 to 30 municipalities in 2012. • Private and public sector workplaces have received support to introduce smoke-free working hours and encourage a better break culture at work. • Methods have been developed to deal with smoking indoors in areas where it is difficult to regulate, such as nursing homes and hospices. • As a consultant and project manager at a health project at Copenhagen’s The Fortifications, the Danish Cancer Society has made a qualitative contribution to the development of innovative activities and physical facilities that promote playing, sports and exercise. • SMIL – Sund Mad i IdrætsLivet (healthy food at sports facilities) – an investigation of best practice to ensure that a healthier diet is offered at cafeterias associated with sports facilities. • The Whole Grain Partnership has contributed to ensuring that whole grain products have become more common. • Update of NORDCAN with 2010 data for all Nordic countries. • The European Cancer Registration project EUROCOURSE has been completed, and the Danish Cancer Society’s role as responsible party for the project on the right to privacy and high standards of ethics in registry research has had a great impact on new EU legislation concerning personal data. •T he media campaign “Switch off the Solarium” has won three awards: Creative Circle, Aurora and the Effectiveness Award. •V olunteers have communicated the sun campaign’s message to childcare institutions, youths and families with children throughout Denmark, thus attracting attention to sun-related issues at a local political level. •C ontinued decline in sunbed use. • The ‘From Car to Bike’ project. • ‘Schoolyard Fun’ is a new partnership aimed at promoting physical activities in the schoolyard. • The ‘Playing on a Line’ (“Leg på streg”) project. • In the research project ‘Calorie Accounts’, the Danish Cancer Society will collaborate with a national daily commodity chain and the University of Copenhagen on a survey dealing with how to make it easier for consumers to make healthier choices without affecting store earnings. • Continued focus on the HPV vaccination and on women in the target group who are difficult to reach. • More female immigrants and refugees should participate in mass screenings for breast cancer and cervical cancer and be vaccinated against HPV. So far, 50 municipal health communicators have been trained to inform about the free offers. •P resentation of the Danish data on trends in the break down of cancer stages on the individual types of cancer. •D evelop resources for collecting data about cancer stages, treatment and comorbidity in relation to individual types of cancer. •D evelop collaboration with clinical databases. •S trive to achieve a ban on solariums for youths below the age of 18. •S trengthen the primary sun advice, shade, in the campaign’s communication, collaboration agreements, structural efforts and other activities. FOCAL POINTS IN 2013 • The evaluation of X:IT will continue at the some 100 schools that participated in the project, and the result of the evaluation will be available in the autumn of 2013. The quit-smoking programmes Xhale and ddsp.dk will also be evaluated. • Xhale will become available as an app. • Give smokers easy access to a variety of efficient methods for quitting smoking in the municipalities. • Further develop the ‘Healthy Together’ model to include communities other than workplaces, particularly public housing projects. • Smoke-free childminder facilities through volunteers in the ‘Clean Air for the Lungs’ project. • Smoke-free working hours. • A new prevention and questioning panel. 25 Danish Cancer Society | Annual Report 2012 “Spending time with others in the same situation is great, because we simply understand each other,” says Stine Legarth, 28, Copenhagen. She is involved in the “Drivkræften” network for young people with cancer, where she functions as a team leader in Copenhagen. 26 patient support People suffering from cancer should be able to lead a fulfilling daily life. The Danish Cancer Society endeavours to provide an optimal framework of counselling and support to cancer patients. Contacts with cancer patients, relatives and the bereaved 2002 – 2012 Contacts 100000 80000 60000 40000 20000 0 2002 2004 2006 2008 2010 2012 27 Danish Cancer Society | Annual Report 2012 PATIENT SUPPORT Patient Support and Community Activities strive to make sure that all cancer patients and their relatives are offered care, knowledge and possible courses of action throughout their cancer pathway. At the same time, the department aims to heighten the visibility of the needs of cancer patients and their relatives and document these needs. Furthermore, it aims to develop new offers for patient support and collaborate with relevant players to disseminate these offers. The Danish Cancer Society currently offers counselling to patients and relatives, either individually or in groups, at more than 30 sites across Denmark. At most of these sites, people may walk in off the street without having made an appointment in advance. The Danish Cancer Society wants to establish a framework which promotes the patient’s own scope of action, and a space where patients and relatives can meet with others in the same situation. In 2013, the first three out of a total of seven new cancer counselling centres will be inaugurated. They will all be in close proximity to the major oncology hospitals. The project is called ‘Living Spaces’ (“Livsrum”). In 2012, Patient Support & Community Activities had almost 75,000 contacts with cancer patients, relatives and the bereaved, who received psychosocial counselling, teaching or participated in activities at the cancer counselling centres. The Danish Cancer Society will be able to offer help and support to far more people affected by cancer when the new centres are ready for use in the years ahead. In terms of community activities, area managers, area consultants and cancer counselling centres have actively participated in launching the rehabilitation and palliation pathway programmes. Furthermore, there has been focus on the preventive effort and providing assistance to regional committees and local units. The department has 138 employees, 102 of which work locally throughout Denmark and 36 are based at the Copenhagen headquarters. LIVING SPACES – HOUSES WITH A HEALING EFFECT The Danish Cancer Society and Realdania will build seven new cancer counselling centres which will be located close to the major cancer treatment hospitals. The project is called Living Spaces and the keywords are safety, homeliness and presence. The first counselling centre will open in Næstved in June 2013. The Danish Cancer Society is in contact with people affected by cancer – patients, relatives and the bereaved – every day. They have one thing in common: they need help to find their way in a new reality. “But we know that a large group of people find it difficult to be proactive and seek help. And many people are not even aware of our patient support activities. We want to change this, and this is the background for the ‘living spaces’ project,” says Laila Walther, head of department. 28 A living space for everyone Together with Realdania, the Danish Cancer Society will build seven new cancer counselling centres. The new ‘living spaces’ will be built in close proximity to the oncology departments in Aalborg, Herning, Vejle, Odense, Roskilde, Næstved and Herlev. In Næstved, Aalborg and Vejle, construction work is already far advanced, and the counselling centre in Næstved will open in June. The centres in Aalborg and Patient support YOUTHS WITH CANCER: YOU ARE NOT ALONE Although there is never a good time to be diagnosed with cancer, the consequences are especially severe for young people. They are on the threshold of life – about to begin or complete their education, find a job, partner or start a family. The Danish Cancer Society focuses on young people and cancer. Vejle will follow in July and September, respectively. Ground has been broken for the counselling centre in Odense, and the construction of the centres in Roskilde and Herning will start in the spring and is expected to be finished by late 2013 or early 2014, concurrently with the centre in Odense. In Vejle, the counselling centre will open in conjunction with the palliative day team, and in Odense and Aalborg, the hospitals have decided to offer ‘Body and Cancer’ – physical exercise activities – to cancer patients receiving treatment, at the cancer counselling centres. The last ’living space’ will be built close to Herlev Hospital. As soon as a suitable building site becomes available, the Danish Cancer Society and Realdania are ready to start the project. Useful houses Laila Walther is convinced that users will feel welcome in the new counselling centres, because the users of the present centres, volunteers, hospital staff, municipalities and employees at the Danish Cancer Society have all contributed input and ideas. “I’m sure that this will help us build useful well-conceived houses where people will feel welcome and comfortable,” Laila Walther states. Realdania supports the project with DKK 50 million. “I think and act differently from other people my own age. I have had cancer, I have faced death, and inside my head, I am 70 years old,” says 28-year-old Stine Legarth from Copenhagen. Today, Stine Legarth is a volunteer at “Drivkræften”, the network for young people with cancer, where she functions as a team leader in Copenhagen. Stine Legarth was diagnosed with Hodgkin’s lymphatic cancer in 2005. She received chemotherapy and radiation therapy, and in 2006 she was given a clean bill of health. “I had no idea what to do when I found out I had cancer. I didn’t know anybody my own age. And the patients I met during my treatment were much older than me. I felt very lonely,” she says. to pass on my experiences to others. And this has been very well received,” she says. Isolation and loneliness Every year, approx. 1,300 young people aged 15 to 39 are diagnosed with cancer. Incurring a life-threatening disease in the prime of one’s youth is one thing. Having to undergo cancer treatment at a department where the average age usually corresponds to one’s grandparents is another. “Like Stine Legarth, many young people feel isolated and lonely when afflicted with cancer. And they long to meet other young people in the same situation. These are the reasons we give higher priority to working with young people through initiatives such as the ‘Drivkræften’ network,” says Laila Walther. “Drivkræften” is growing Inspired by a stay at the Dallund Rehabilitation Centre with other young people with cancer, she took the initiative to start the “Drivkræften” network in Aarhus back in 2008. “I just didn’t want other young people to feel lonely the way I did. It was so important for me to get the chance Since 2007, cancer patients and survivors in the age group from 15 to 40 have had the opportunity to establish contact with other young people in the same situation via “Drivkræften”. Today, “Drivkræften” has local network groups in Copenhagen, Odense, Aarhus, Vejle and Aalborg, with dedicated young people in charge of activities such as dining together and going to the cinema together. 29 Danish Cancer Society | Annual Report 2012 “I’m a student and sing in several bands, so I’ve got my hands full. But that doesn’t mean I’ll compromise on my voluntary work for Drivkræften. I get energy from my work there, and I’m thrilled to be involved in developing the offers at Drivkræften,” says Stine Legarth. INCURABLE PATIENTS DO NOT GET SUFFICIENT SUPPORT Insufficient collaboration in the healthcare sector, dissatisfaction with efforts targeting relatives and the failure to relieve symptoms such as pain, loss of appetite and depression. For the first time ever, the Danish Cancer Society has identified central themes for incurable Danish cancer patients with a short life expectancy. The Danish Cancer Society is now working to give “Drivkræften” much more visibility at Danish hospital departments, the Society’s cancer counselling centres, the “Drivkræften” website, and on Facebook – all under the motto “You are not alone”. Launching a nation-wide survey The Danish Cancer Society is planning a large nationwide survey to collect knowledge of the special problems experienced by young cancer patients during their cancer pathway. “Our support for young cancer patients must be top quality, so the offers are aimed at their special needs. It is crucial that they receive much more targeted offers to improve their quality of life,” states Laila Walther. 30 Almost 550 severely ill cancer patients provided input for a “Barometer Survey” by the Danish Cancer Society concerning cancer patients’ perception of the palliative phase of life. Insufficient relief of symptoms ing of not receiving sufficient care,” says Laila Walther, head of department. Healthcare sector collaboration must be strengthened One-third of the patients experienced some or serious pain. More than half were very tired, half had no appetite and many suffered from anxiety and depression. In the survey, they were asked whether they felt they had received sufficient palliative care to relieve their symptoms. Almost one-third of the patients expressed that they had not received sufficient care. Furthermore, the patients felt that the collaboration between the different segments of the healthcare sector was not up to par. One out of four patients did not have the impression that the hospital and the GP collaborated well. One in five did not find that there was good collaboration between the hospital, the GP and the home-care service, and one in ten did not experience good collaboration between the GP and the palliative team/hospice. “This is not good enough, because palliation of physical symptoms such as pain, fatigue, loss of appetite and nausea, as well as of the severe mental stress associated with the disease, are obvious core areas in the palliative effort. I know that not all symptoms can be fully relieved, but it is unsatisfactory that so many people have a feel- “It is of crucial importance that the home-care service, GPs, palliative teams, hospices and hospitals form a long and coherent chain. Not until all levels of the chain use each other in the best possible way and agree on how to solve the task will we be able to provide a terminal patient with optimal care,” says Laila Walther. Patient support RESULTS IN 2012 Neglected relatives Across hospitals, GPs, home-care services and the palliative teams/hospices, there was major dissatisfaction with the staff’s interest in the relatives’ situation. The same applied to the staff’s involvement of relatives in the patients’ treatment. Every third patient was dissatisfied with this in relation to the hospital’s effort, and one in four expressed dissatisfaction with the home-care service in this respect. “It is quite obvious that the healthcare sector is not doing a good enough job in relation to the relatives. We know how much it means to the patient that the relatives get involved, because they constitute the most important resource for the patient in every respect. This is an important focus area which we are striving to improve. The relatives need to get involved and receive support,” says Laila Walther. The Barometer Survey launched by the Danish Cancer Society Central Board is the most comprehensive of its kind so far. “Even though ‘only’ 550 patients participate in the survey, the results are extremely important, because they represent the experiences of a group of patients who are rarely listened to,” says Laila Walther, and adds: “A major development and expansion is going on these years when it comes to palliative care for incurable and terminal patients. But we still have a long way to go. One of the outcomes of this survey will be to stimulate a discussion of how we can best improve our efforts.” •T he ground has been broken for three ’living spaces’. A winner has been found for the construction project in Odense, and the architecture competition for Herning and Roskilde has been announced. •A patient-support strategy has been developed to set clear goals for patient-support efforts and the involvement of new target groups. • In collaboration with the Palliative Research Unit at Bispebjerg Hospital, a barometer survey has been conducted which focuses on cancer patients’ needs and experiences in the late palliative phase. •A t Rigshospitalet and Herlev Hospital, well-functioning patient representative groups have been set up to advise on patients’ needs. The department has evaluated the project and will disseminate the lessons learned. • In connection with the implementation of the rehabilitation and palliation programme, the department has been represented in working groups set up in the five regions, and has organised theme days and contributed to municipal rehabilitation efforts. • Special focus on young people with cancer • The Dallund Rehabilitation Centre was included in the Finance and Appropriations Act for 2012. As at 1 January 2013, the Region of Southern Denmark took over responsibility for this. Initially, the Centre will continue to offer rehabilitation courses to cancer patients who have completed treatment. FOCAL POINTS IN 2013 • Inauguration of the first three ’living spaces’. Six construction projects in the pipeline. • In collaboration with other departments at the Danish Cancer Society, Patient Support will launch a Navigation Project where volunteers will be trained to help vulnerable cancer patients navigate the treatment pathway. •C ontribution to the development of digital support offers and other digital tools which can help cancer patients deal with their own problems and longterm sequelae. The department will establish a network for researchers in the field and contribute to testing four concrete digital tools. • Offer of online counselling. • Focus on young people with cancer and on children whose relatives have cancer, and development of offers targeted particularly at these groups. • Close monitoring of the municipal rehabilitation effort and creating a complete overview of the effort all across Denmark. • Follow-up on cancer patients’ needs in the palliative phase and dialogue with professional environments on finding solutions. 31 Danish Cancer Society | Annual Report 2012 ACHIEVEMENTS IN 2012 “Beat Ca ncer” ra Cancer.d k Cancer p atients a nd relativ most imp es are th ortant ta e largest rget grou Society’s and p of the website, Danish C c a ncer.dk. Cancer.d a ncer k is one o f the mo Danish s s t compre ites and hensive attracted visitors in almost th 2012. Th re e million e site is co updated ntinuous with sup ly p o being rt about ca and the la ncer dise test know a s e ledge s been enh , and mo st recentl anced in the psyc y it has hosocial area. 12 FACEBOOK PAGES Facebook is one of the media channels that the Danish Cancer Society has made most use of to interact with users. So far, the Society has 12 Facebook pages aimed at different target groups. ‘Support for the Breasts’ has almost 500,000 fans, which makes it one of the largest in Denmark, whereas the Danish Cancer Society’s general Facebook profile has 180,000 fans. ised DK Denmark K 100 m ’s largest illion e ffort aga million fo inst canc r the Dan e r ra is ised DKK h Cancer 43. In a n 100 Society o umber o n T V2 in f shows cancer a a week ll week lon nd fundra g, TV2 fo ising. This “Beat Ca cused on culminate ncer ” fun d d in the big ra iser show In all, the live on Saturd different ay, 27 O shows du week rea c tober. ring the ched mo Beat Can re than 3 B eat C a n cer .4 million cer live s viewers, how was million D and the watched anes. In o b y more th n ly given mo two wee an 1.6 ks, the c re than 1 ampaign 00,000 In week w li k as e s on Face 44, 89% b o ok . of all Dan asked wh es answe ether the red ‘yes’ y h a d se Danish C wh e n en, heard ancer So or read a ciety in th week, 68 b o ut the e m % of Dan edia, and es indica in the sa or very p te me d ositive im that they pression had a po of Beat C sitive ancer. Relay for Life More members At the end of 2012, 466,215 private individuals and families were members of the Danish Cancer Society, compared to 464,736 in 2011. The reason for the slight membership increase is that, as expected, there has been a slightly larger dropout in 2012 as a result of the membership fee increase adopted at the meeting of the Danish Cancer Society’s Committee of Representatives in May. In 2012, the Relay for Life was held in 16 cities. Some 12,400 Danes took part in the relay races, including 2,000 current and former cancer patients, who are given hope by being part of the event. The relay races raised DKK 3.2 million. RECORD INCOME FROM LOTTERIES Once again in 2012, the 10 lotteries yielded an impressive income of DKK 67.5 million, against DKK 57.7 million in 2011. Patient safety along the cancer pathway Under the auspices of the National Taskforce, Quality & Patient Safety has been involved in drawing up a set of national recommendations which will improve the safety of cancer treatment, focussing on chemotherapy, radiation therapy, infections, patient involvement, etc. The taskforce has been set up in collaboration with the Danish Multidisciplinary Cancer Groups (DMCG) and Danish Regions. www.frivillig.dk In October, Volunteering launched www. frivillig.dk – the Danish Cancer Society’s universe for volunteers. During the first two months, almost people 900 40,000 volunteers Without volunteers, the Danish Cancer Society would never be able to carry out the Society’s ongoing tasks. In 2012, more than 40,000 people chose to spend their leisure time helping the Danish Cancer Society. This equals some 560 full-time positions. “There’s no way we could provide the amount of research and the help we offer to cancer patients without the huge efforts of our volunteers,” says Leif Vestergaard Pedersen, managing director of the Danish Cancer Society. had created a profile. The profiles have been used actively to post volunteer jobs, advertise local events, establish collaborative groups, etc. Pink Cup Pink Cup – Denmark’s largest golf tournament for women – raised more than DKK 3.1 million for the breast cancer cause. Since it was begun in 2003, the Pink Cup tournament has raised DKK 20.8 million. g policy teerin New volun g policy volunteerin ’s ty e ci o S een Cancer ration betw The Danish ose collabo cl in e p u th n t ou was draw ees. It sets ng and employ by answeri rk o w volunteers ry ta n lu o v for the framework ch as: su s question olunteer? aims ecome a v r Society’s Who can b nish Cance a D e th re What a rk? luntary wo for the vo THE PATIENT APP “LIVING WITH CANCER” The Danish Cancer society won the UN ‘World Summit Award Mobile 2012’ for the patient app ‘Living with Cancer’ (“Liv Med Kræft”). The app was developed to address the needs of cancer patients and relatives to manage and keep track of the cancer pathway. The app includes a number of functions which aim to make living with cancer a little bit easier. For instance, it is possible to create a log of the cancer pathway which keeps track of everything that has happened along the way. And it contains a checklist with possible questions for doctors, employees, family and friends. The users are satisfied: 80.2% are returning visitors and 19.8% of the visitors are new. The most popular pages are: Profile, log, checklist and calendar. Recycling is hot In Septembe r, the Danish Cancer Soci eleventh IGEN ety’s shop opened in Odense. T new thrift sh he op has got of f to a good st with a turnov art er of DKK 50 0,000 during the first thre e months. More than 6 00 people do voluntary w in the shops, ork which had a co mbined turn ver of approx o. DKK 19 mill ion in 2012. National fundraising More than 30,000 2.6 Danes visited million homes for the year's national fundraising drive on 25 March, which raised DKK 30.5 r surveys Baromete and 2 1 r Surveys, e Baromete th n o d e Bas ption of ients’ perce cancer pat t and follow n , treatme n io at in m aexa been an ospitals has up at the h erformed p rvey was su e h T . al, d lyse ejle Hospit tion with V ra o b lla o g co in ve its al ing to achie v ri st is h ic wh s when it world-clas g in m al, co e b of ients optim ffering pat o to s e m co therapy. -designed individually million. 33 Danish Cancer Society | Annual Report 2012 Focal Points in 2013 Policy and Legal Advice • The policy work in the Executive Committee and Central Board of the Society • Pursue political goals on a national level • Work on the Danish Cancer Society’s goals towards 2020 Management Policy and Legal Advice HR Volunteering • Strategy for the voluntary work at the Danish Cancer Society • Relay for Life in seven additional cities • One or two more thrift shops and a web shop for second-hand products Volunteering Fundraising & Membership Patient Support & Community Activities Fundraising & Membership • Recruit 25,000-30,000 new members •T en-year anniversary for the Support for Breasts campaign. Revitalisation of the campaign • ‘Danes on Bikes’ – cycling race attracting 15,000 participants across 8 Danish cities. Fundraising target of DKK 1.5m net Patient Support & Community Activities • Inauguration of the first three ‘living spaces’. • Navigator project training volunteers to help vulnerable cancer patients navigate the treatment pathway • Offer of online counselling. Focal Points in 2013 Communications • Strengthen the Danish Cancer Society’s high profile in the media and the general public • Increase the use of social media, including mobile units • Increase the web TV production at cancer.dk Communications Department Finances & Administration The Danish Cancer Society Research Center Cancer Prevention & Documentation Quality & Patient Safety • Identify environmental factors (particularly traffic pollution), work environment and lifestyles which increase the risk of cancer and weaken the prognosis for cancer patients • Post-treatment health-impairment sequelae in adult cancer survivors • Chart the mechanisms associated with cellular stress and cancer development The Danish Cancer Society Research Center Cancer Prevention & Documentation • Information campaign on intestinal cancer. •S trive to achieve a ban on solariums for youths below the age of 18. •G ive smokers easy access to a variety of efficient methods for quitting smoking in the municipalities. Quality & Patient Safety • Develop a requirements-based model to assist the healthcare system in following up on the patient after completed cancer treatment • Continue to strengthen the involvement of patients and relatives as partners in research and development of the healthcare system •C arry out development projects with patients and clinicians in order to incorporate the patients’ own information about healthrelated vitality in clinical practice 35 Finances From 2008 to 2012, the Danish Cancer Society’s expenses targeting the Society’s main objectives, etc., increased by DKK 125m to DKK 569m. Expenses for the Danish Cancer Society’s main objectives DKK million 600 500 400 300 2008 36 2009 2010 2011 2012 Socialising and exercising with like-minded people means a lot to Mette Bloch Kristiansen, 50. Mette was diagnosed with rectal cancer eight years ago and has had five recurrences since then. “I’m currently free from disease and treatment and back on my job. That’s great, but it doesn’t mean I’ll cut down on exercising and spending time with the others. That’s one thing I can’t do without,” says Mette Bloch Kristiansen. 37 Danish Cancer Society | Annual Report 2012 38 Finances Key figures for five years Income has grown by DKK 129.2m to a total of DKK 664.4m in the five-year period from 2008 to 2012, equivalent to an increase of more than 24%. The most significant increase is seen from 2011 to 2012 where the Danish Cancer Society carried out the Beat Cancer campaign in collaboration with TV2, focusing on the fight against cancer through a series of events and TV programmes. The item Funds collected, which includes income from legacies and bequests, membership fees, national collections, grants for specific projects, etc., amounts to DKK 505.3m in 2012, up DKK 116.0m or almost 30% over the five-year period. Legacy income has declined over the five-year period from DKK 171.8m in 2008 to DKK 149.4m in 2012, equivalent to a decline of DKK 22.4m or 13%. The reason for this decline is lower proceeds per legacy case. Membership fees, etc., increased over the five-year period from DKK 82.6m in 2008 to DKK 120.6m in 2012, equivalent to an increase of DKK 38.0m. In the same period, the membership has increased from 430,484 to 466,215. External grants for specific projects rose from DKK 66.5m in 2008 to DKK 96.8m in 2012, equivalent to an increase of DKK 30.3m or almost 46%. Income from national fundraising drives has increased from DKK 32.7m to DKK 102.6m, equivalent to an increase of DKK 69.9m. The 2012 Beat Cancer campaign is the most important reason for the increase, whereas income from door-to-door fundraising has maintained a relatively stable level of about DKK 30m in the fiveyear-period. The profit from Lotteries, recycling and sale of goods amounts to DKK 112.3m in 2012, which is an increase of DKK 34.6m or almost 45% during the five-year period. Capital income, comprising interest, dividends and rental income received, has declined by DKK 25.9m during the five-year period and amounts to DKK 11.2m in 2012. The decline in this income is, to a large extent, attributable to lower interest-rate levels during the period, as well as declining rental income due to Denmark’s School of Design’s vacation of the Society’s buildings in 2011. At DKK 35.6m, Government grants reached its highest level for the five-year period in 2012 due to grants for the Dallund Rehabilitation Centre which was transferred to the Region of Southern Denmark on 1 January 2013. The Fundraising & Membership department’s regular and project expenses, consisting of salaries and project expenses for member services, analyses and development of new forms of income and games, amount to DKK 68.3m in 2012. This is an increase of DKK 2.9m compared to 2011. Compared to 2008, the aggregate increase is DKK 14.5m, or almost 27%. The amount should be viewed in relation to the increase in income in the five-year period. Research expenditure fluctuated during the period from a low of DKK 214.0m in 2008, to DKK 278.6m in 2012. This is an increase of DKK 64.6m, or 30% compared to 2008. From 2008 to 2009, research expenditure rose from DKK 214.0m to DKK 279.1m which is the highest level of spending on research in the five-year period, mainly due to a marked increase in the distribution of strategic funds. A higher level of distribution of strategic funds is also the main reason for the increase in research expenditure from DKK 240.5m in 2011 to DKK 278.6m in 2012. Expenses for Patient Support & Community activities amount to DKK 131.0m in 2012, the highest level in the five-year period, representing an increase of DKK 36.4m, or some 38% compared to 2008. Information expenses, including expenditure on Prevention & Documentation, Communications and Volunteering, increased steadily during the period. In 2012, these activities amounted to DKK 104.0m, corresponding to an increase of DKK 22.7m, or 28% compared to 2008. Administrative expenses amounted to DKK 35.5m in 2012, which represents an increase of DKK 8.7m over the five-year period. The reason is primarily a rise in common staff expenses. The most significant asset item is the Securities portfolio which has varied in the five-year period from a low of DKK 541.7m in 2008 to a high in 2010 where the asset item amounted to DKK 706.3m. In 2012, the amount was DKK 678.2m. The fluctuations are primarily due to value adjustments following changed interest-rate levels and subsequent declines or increases in the securities portfolio and handsome share price increases in 2009 and 2010, followed by sharply declining share prices in 2008 and 2011. Due to a portfolio restructure, 2012 also saw a major shift from securities to cash, precisely on the balance sheet date, 31 December 2012. 39 Danish Cancer Society | Annual Report 2012 KEY FIGURES FOR FIVE YEARS Income statement (DKK 1,000) 2008 2009 2010 2011 2012 389,282 77,729 37,087 31,114 421,607 94,173 25,443 30,482 452,752 96,763 24,211 28,865 415,760 98,953 12,584 28,893 505,294 112,293 11,182 35,641 535,212 571,705 602,591 556,190 664,410 -53,798 -61,809 -64,551 -65,431 -68,294 481,414 509,896 538,040 490,759 596,116 214,002 94,603 81,233 26,788 22,789 4,554 279,090 123,766 84,375 31,020 28,003 4,666 241,729 124,575 89,558 33,109 25,324 4,666 240,479 128,215 94,446 34,550 19,195 3,785 278,587 130,954 103,955 35,483 16,303 3,785 443,969 550,920 518,961 520,670 569,067 For use in subsequent years 37,445 -41,024 19,079 -29,911 27,049 Balance sheet (DKK 1,000) 2008 2009 2010 2011 2012 221,850 541,668 120,403 51,058 216,456 629,639 118,609 64,270 177,823 706,312 97,137 62,147 167,225 703,219 43,936 85,427 164,940 678,212 160,151 104,980 934,979 1,028,974 1,043,419 999,807 1,108,283 549,883 139,223 245,873 610,755 181,184 237,035 635,976 173,801 233,642 592,184 169,432 238,191 672,661 195,358 239,370 934,979 1,028,974 1,043,419 999,807 1,107,389 Funds collected Lotteries, recycling, sale of goods, etc. Capital income Government grants Total income Expenses for the Fundraising & Membership Department’s regular and project activities Total net income Research Patient Support & Community Activities Information Administrative expenses Improvement of buildings and technical investments, etc. Depreciation and amortisation Total expenses Properties Securities and shares in Kræftens Bekæmpelses Forlag Cash Sundry receivables Total assets Equity Grants for scientific work not yet used Sundry payable expenses and legacy amounts on account Total equity and liabilities 40 Finances Income statement in pct. 2008 2009 2010 2011 2012 72.7 14.5 7.0 5.8 73.7 16.5 4.5 5.3 75.1 16.1 4.0 4.8 74.8 17.8 2.2 5.2 76.0 16.9 1.7 5.4 100.0 100.0 100.0 100.0 100.0 51.4 22.7 19.5 6.4 53.9 23.9 16.3 6.0 49.4 25.5 18.3 6.8 48.3 25.8 19.0 6.9 50.7 23.9 18.9 6.5 100.0 100.0 100.0 100.0 100.0 Distribution of income in pct. Funds collected Lotteries, recycling, sale of goods, etc. Capital income Government grants Distribution of expenses in pct. Research Patient Support & Community Activities Information Administrative expenses 41 Danish Cancer Society | Annual Report 2012 Selected key information (DKK 1,000) 2008 2009 2010 2011 2012 562 619 631 646 652 Membership numbers Membership fees, etc. received Contribution per member in DKK 430,484 82,632 192 448,050 97,325 217 459,850 104,887 228 464,736 104,120 224 466,215 120,575 259 Gross income Gross expenditure Expenses for the Fundraising & Membership Department’s regular and project activities Net income 609,454 74,242 53,798 481,414 652,773 81,068 61,809 509,896 683,905 81,314 64,551 538,040 643,055 86,865 65,431 490,759 764,787 100,377 68,294 596,116 Legacy income Number of legacy cases completed Proceeds per legacy case 171,796 258 666 173,557 284 611 175,473 299 587 150,768 286 527 149,379 272 549 External grants for specific projects 66,469 87,575 104,891 95,163 96,781 No. of collectors for door-to-door fundraising Profit from door-to-door fundraising Profit per collector in DKK 27,000 27,495 1,018 28,000 27,706 990 29,000 29,486 1,017 31,000 25,765 831 31,000 25,670 828 Profit from lotteries 44,840 57,289 53,707 57,681 67,540 Profit from events and sale of products 31,170 34,373 40,732 37,533 40,389 Government grants 31,114 30,482 28,865 28,893 35,641 -20.3 19.6 8.7 -0.6 9.5 59 59 61 59 61 No. of employees translated to man-years Return as a percentage of securities portfolio incl. market value adjustments Solvency ratio (Equity as a percentage of total assets) 42 Finances 2012 FINANCIAL REVIEW Introduction The Danish Cancer Society’s net income for the year totalled DKK 596.1m. The year’s expenses for the Society’s activities totalled DKK 569.1m. This results in a profit of DKK 27.0m. Income The gross income of the Danish Cancer Society amounts to DKK 764.8m in the 2012 financial year, against DKK 643.1m the previous year. After deducting expenses for activities such as lotteries, national fundraising drives, thrift shops, other events and product sales, capital income and expenses for the Fundraising & Membership department’s regular and project activities totalling DKK 168.7m, the result is a total net income of DKK 596.1m, equivalent to a increase of DKK 105.3m, compared to last year. Out of the increase of DKK 105.3m, the profit from the new Beat Cancer campaign amounts to DKK 91.3m. Income 2003-2012 DKK million 800 600 400 200 0 Income from Legacies and testamentary bequests (note 1) declined to DKK 149.4m in 2012, from DKK 150.8m in 2011. Fewer legacy cases were completed than last year, with 272 cases in 2012 against 286 cases in 2011. The average proceeds per legacy case are up from DKK 0.527m in 2011 to DKK 0.549m in 2012. Membership fees and contributions from members and regular contributors (note 1) amounted to DKK 120.6m in 2012, against DKK 104.1m in 2011, equivalent to an increase in income of DKK 16.5m. This is mainly due to an increase in membership fees. At the end of 2012, 466,215 members were registered, against 464,736 the previous year, i.e. a membership increase of 1,479. In 2012, the Danish Cancer Society Research Center, information activities and Patient Support & Community Activities received External grants for specific projects (note 1) totalling DKK 96.8m, which represents an increase of DKK 1.6m compared to 2011. Gross income Net income The item Corporate (note 1), comprising research gifts, corporate memberships and co-promotion and events, amounted to DKK 23.7m in 2012, against DKK 24.6m in 2011. Gifts and grants (note 1) amounted to DKK 3.2m in 2012, against DKK 4.3m in 2011. The annual door-to-door fundraising (note 1) was held on Sunday, 25 March. The net profit was DKK 25.7 million, compared to DKK 25.8 million in 2011. As in previous years, the fundraising drive comprised all of Denmark’s 98 municipalities, and the door-to-door event involved more than 31,000 volunteers as collectors, organisers and assistants. The Danish Cancer Society’s door-to-door fundraising continues to be the largest of its kind in Denmark. Income 2012 Income 2012 Income 2011-2012 DKK million 160 Corporate 4% Capital income 2% Corporate 4% Specific project grants 15% Capital income 2% Other income 7% Specific project grants 15% Government grants 5% Government grants 5% Legacy income 23% Other income Lotteries 10% 7% 80 Legacy income 23% Contributions from foundations 1% Contributions from Lotteries 10% National collections 15% National collections 15% Membership fees 18% Membership fees 40 foundations 1% 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Contributions from foundations (note 1) amounts to DKK 9.1m, which is an increase of DKK 2.2m compared to last year. The increase is due to distribution of realised capital gains. 18% 120 0 G C Lo O N S C G C Me Le mb gac orpo ifts ontr pecif ation tter apita over ther rat and ibu nm ies ic l inc ers y in a i l n e co o e hip co gra tion proj coll me nt g me ec ec nts s f fee me ran t t r i o o gra s m n ts s fou nts nd ati on s 43 2011 2012 Danish Cancer Society | Annual Report 2012 Door-to-door fundraising DKK 1,000 2012 2011 Income 31,545 31,625 Expenses 5,875 5,860 Net profit 25,670 25,765 Number of collectors 31,000 31,000 Beat Cancer campaign on TV2 Teamed up with TV2, the Danish Cancer Society carried out the Beat Cancer campaign in week 43. In a number of shows throughout the entire week, TV2 had focus on cancer while raising money to the Danish Cancer Society. This all culminated in the great Beat Cancer Live fundraiser show on TV2 on Saturday, 27 October. Beat Cancer DKK 1,000 2012 Income 102,531 Expenses 11,214 Net profit 91,317 2011 - The gross income from Beat Cancer 2012 totals DKK 102.5m, including the proceeds from the Beat Cancer lottery delivered to every household. In addition to the Beat Cancer lottery, income sources include lotteries and donations via text messaging/phone, online donations, auctions and corporate donations. The net proceeds of Beat Cancer amounted to DKK 91.3m, which are included under National collections at the amount of DKK 76.5m (note 1) and under Lotteries (note 2) at the amount of DKK 14.8m. The Support for the Breasts campaign generated net proceeds of DKK 7.7m in 2012 compared to DKK 44 Distribution of profits from the Beat Cancer campaign: DKK m 7.5 15.0 7.5 Research into causes of cancer: Widening of Denmark's largest population survey, Diet, Cancer and Health, to cover three generations 15.0 Research into prostate cancer with a focus on improved diagnosis methods and individualised therapies 15.0 Research into cancer patients’ comorbidity and research into the social disparity that characterises the general public health and well-being 12.0 Information campaign on colon cancer 5.0 Investigation of the patients’ assessment of the effect of their cancer treatment aimed at preventing errors and complications in the cancer therapy 3.0 11.3 Total 91.3 Research into early diagnosis and cancer diagnosis improvements 1) Research into rehabilitation for cancer patients during and after treatment and support for a good life after cancer Research into improved cancer prevention and the most effective prevention types Ongoing support for sundry cancer projects (patient support) 1) 1) 1) 1) The total amount of DKK 41.3m was distributed in 2012. 14.4m in 2011. The sharp decline of DKK 6.7m is mainly due to the discontinuation of the Breast Gala on TV3 in consequence of the new Beat Cancer partnership with TV2. In 2012, the campaign also experienced a decline in the proceeds from the sale of bracelets as well as a decline in selected corporate partners. The Danish Cancer Society fights breast cancer on many fronts. Breast cancer is a high-profile focus area because it affects 4,000 Danish women every year. The profile is so high that the Danish Cancer Society has an earmarked breast-cancer fundraising campaign: Support for the Breasts. Other activities, such as corporate and individual donations and the Pink Cup golf tournament, raised an additional DKK 7.0m. This means that a total of DKK 14.7m was collected for breast cancer in 2012. In 2011, the amount was DKK 19.6m. Whatever is collected one year is spent the next. Regardless of the results of other collections for the Danish Cancer Society, we can be sure that breast cancer gets at least the proceeds from the earmarked fundraising. The funding need is considerable, however, so the Cancer Society adds a substantial amount to the funds collected. Finances Lotteries, recycling, sale of goods, etc. (note 2) shows the profit from lotteries totalled DKK 67.5m in 2012, against DKK 57.7m in 2011, representing an increase of DKK 9.8m, which secures the highest total profit from lotteries since 1991. The increase is largely attributable to the publicity on TV2 in the week leading up to the Beat Cancer show, which meant that the door-to-door-delivered Beat Cancer lottery reached a turnover of DKK 22.0m. Income from the individual lotteries continues to vary considerably, and it is therefore expected that it will be difficult to maintain the high level of income in this highly competitive market. The Danish Cancer Society’s ten Thrift shops (note 2) under the IGEN brand generated their best-ever performance in 2012. The profit was DKK 4.4m in 2012, compared to DKK 3.9m in 2011. The increase is partly due to the chain’s opening of shop no. 11 in Odense last September, and partly due to success in the other shops. IGEN Income Expenses Net profit DKK 1,000 Number of shops Number of volunteers 2012 18,907 14,543 4,364 2011 17,192 13,246 3,946 11 672 10 546 The profit from Other events and product sales (note 2) increased to DKK 40.4m in 2012 compared to DKK 37.3m in 2011, up by DKK 3.1m. The increase is primarily attributable to increased VAT refunds of DKK 1.8m. In addition, the decline in breast cancer income is offset by higher income from new activities such as Men & Cancer and ‘Danes on bikes’/Alpe d’Huez with a total increase of approx. DKK 2.5m in 2012 compared to 2011. Relay for Life was held in 16 cities in 2012, generating an aggregate profit of DKK 3.2m, which is an increase of DKK 1.4m compared to 2011. The relay events attract more and more teams and the fundraising is more intensive than previously. Relay for Life DKK 1,000 2012 2011 Income 3,666 2,017 Expenses 459 210 Net profit 3,207 1,807 Expenses 2011-2012 DKK million 300 250 200 150 100 50 0 Number of participants Number of relays 12,400 16 7,200 10 2011 2012 Re s ea rc h Inf Co Pa orm mm tie un nt S ati ity up on Ac por tiv t & itie s Ad mi de Bu pre ild cia ing tio im tio n pro n nis tra Expenses related to Fundraising & Members, department and project activities (note 3) is up DKK 2.9m to a total of DKK 68.3m in 2012 as a result of increased activities. ding from the Danish Ministry of Health in the amount of DKK 11.9m. As at 1 January 2013, the centre was transferred to the Region of Southern Denmark. Capital income (note 4) amounts to DKK 11.2m in 2012, against DKK 12.6m in 2011. The return on securities was at DKK 15.0m in 2012, against DKK 10.0m in 2011, which is mainly due to higher returns on shares. Rental income resulted in a loss of DKK 3.8m in 2012. The loss was mainly due to Denmark’s School of Design’s vacation of premises in May 2011 and the resulting vacancy. Expenses Government grants (note 5) which mainly includes grants from the Danish pools and lottery funds and from the Danish regions, amounted to DKK 35.7m in 2012. Grants from the pools and lottery funds amounted to DKK 17.5m in 2012, against DKK 18.7m in 2011. The grants to the cancer counselling centres amounted to DKK 6.3m in 2012, compared to DKK 7.2m in 2011. In 2012, the Dallund Rehabilitation Centre received fun- v./ The aggregate expenses in 2012 for research, patient support & community activities, information, administration, building improvement, technical investments, etc., as well as depreciation and amortisation amounted to DKK 569.1m, against DKK 520.7m in 2011, equivalent to an increase of DKK 48.4m. The increase is mainly attributable to research expenditure which increases by DKK 38.1m from DKK 240.5m to DKK 278.6m. Administrative expenses (note 6) covers a number of common functions, such as the Executive Committee, committees and the management. This also includes finances, IT and shared property and staff administration. These expenses amounted to DKK 35.5m in 2012, which is DKK 0.9m higher than in 2011. 45 Danish Cancer Society | Annual Report 2012 Expenses 2012 Information 19% Administration 6% Research 51% Patient Support & Community Activities 24% Expenses for Improvement of buildings, technical investments, etc., (note 7) amounted to DKK 16.3m in 2012, against DKK 19.2m in 2011. The decline of DKK 2.9m is composed of lower expenses for improvements of research premises and office facilities as well as higher expenses for current IT projects. Research expenditure (note 8) amounted to DKK 278.6m in 2012, against DKK 240.5m in 2011. This increase of DKK 38.1m is composed of higher expenses for operating own research departments of DKK 3.8m, an increase relating to quality & patient safety of DKK 3.1m, lower grants from the scientific committees of DKK 19.2m and an increase of DKK 50.4m concerning the strategic distributions. The operation of own research departments increased from DKK 116.2m in 2011 to DKK 120.1m in 2012. DKK 2.3m of this increase is attributable to an increase in Externally funded projects which accounts for a total of DKK 48.5m of the departments’ activities. 46 Grants from the research committees and the Central Board amounted to DKK 79.0m in 2012 compared to DKK 98.2m in 2011 and have thus declined by DKK 19.2m. The decline is primarily due to lower grants from the Danish Cancer Society’s Scientific Committee of DKK 19.5m from DKK 79.2m in 2011 to DKK 59.7m in 2012. Expenses for Patient Support & Community Activities (note 9) amounted to DKK 131.0m in 2012, against DKK 128.2m in 2011. Disregarding externally funded projects and expenses for the Dallund Rehabilitation Centre, the 2012 amount is DKK 105.2m, against DKK 103.5 in 2011, representing an increase of DKK 1.7m. In 2012, expenses for the Dallund Rehabilitation Centre aggregated DKK 11.9m. The Dallund Rehabilitation Centre received funding from the Danish Ministry of Health in the amount of DKK 11.9m in 2012. As at 1 January 2013, the centre was transferred to the Region of Southern Denmark. Information expenses (note 10) increased by DKK 9.5m to DKK 104.0m in 2012. The increase is attributable to increasing activities concerning Cancer Prevention & Documentation in the amount of DKK 4.0m, an increase concerning Communications of DKK 2.0m, an increase in Volunteering of DKK 1.7m, an increase in externally funded projects of DKK 1.6m and an increase in General information via lotteries of DKK 0.2m. Balance sheet The book value of the Society’s rental properties (note 12) is DKK 164.9m in 2012, against DKK 167.2m in 2011. Among the elements in the decline of DKK 2.3m are depreciation on rental properties of DKK 3.8m and additions of DKK 1.5m during the year for properties conveyed by inheritance. The public land-assessment value of these rental properties is DKK 283.6m. Sundry receivables, pre-paid expenses, etc. (note 13) increased from DKK 63.8m to DKK 83.4m in 2012. The increase of DKK 19.6m is mainly due to amounts receivable for the Beat Cancer campaign in October 2012, as part of the amounts are yet to be settled by the telecom carriers. The Securities portfolio (note 14), consisting of bonds, shares and mortgages, is the major asset on the balance sheet. The portfolio decreased by DKK 25.0m to DKK 677.2m in 2012. This decline is composed of a decline in the share portfolio of DKK 44.7m to DKK 128.2m and an increase in the bond portfolio of DKK 19.7m to DKK 545.8m. The Danish Cancer Society follows an investment strategy of optimising returns on the Society’s assets for the benefit of cancer patients, with due consideration for composing a widely diversified, prudent and conservative portfolio. To implement this strategy, the Society works with some of the most renowned asset managers, which are Nykredit Asset Management, Danske Capital, Nordea Investment Management and PFA Kapitalforvaltning. The operating fund (note 15) amounted to DKK 398.0m at the end of 2012, against DKK 447.7m at the end of 2011. The operating fund was allocated in 2013, as the Central Board has approved activities of DKK 470.9m. The elements in the decline of DKK 49.7m are the profit of the year of DKK 27.0m less a Reserve for Beat Cancer and a Reserve for Strategic initiatives of DKK 50.0m and DKK 26.7m respectively. Finances Distribution among main activities in 2012 for the Society’s 652 employees Composition of assets Assets totalling DKK 1,108m. Securities 61% Cash 14% Administration 62 Fundraising & Membership 91 External research departments 43 Properties 15% Own research departments 189 Receivables 10% Reserve for Beat Cancer distribution (note 16). It was decided to distribute the profit of DKK 91.3m from the Society’s Beat Cancer campaign to already described initiatives. DKK 41.3m were used in 2012, and DKK 50.0m consequently remain for subsequent distribution. This amount has been placed in a special reserve. The amount is taken from the operating fund. Reserve for strategic initiatives (note 17). It was decided in 2009 to earmark DKK 30.0m a year from 2010 to 2019 for strategic research initiatives, corresponding to a total of DKK 90.0m for the years 2010, 2011 and 2012. By the end of 2012, a total of DKK 63.3m of these funds had been used, and the accumulated underconsumption amounts to DKK 26.7m. This amount was taken from the operating fund in 2012 and placed in a special reserve. The Value adjustment fund (note 18) amounts to DKK 133.9m at the end of 2012. Compared to last year, this Patient Support & Community Activities 165 Information/ Communications 102 is an increase of DKK 53.4m. This increase is composed of a capital gain on bonds and shares of DKK 35.0m and DKK 19.7m, respectively, and a foreign exchange loss of DKK 1.3m. Interest rate risk/Price risk The latent price risk resting on the Society’s bond portfolio, with a duration of 3.0 (average remaining term), will result in a decrease of DKK 16.2m, if the interest rate increases by 1%. The Society’s value adjustment fund, amounting to DKK 133.9m at year-end 2012, will thus be able to counter a price decline in the bond portfolio corresponding to an interest rate increase of 8.3%. Number of employees The Society employed 652 FTEs at the end of 2012, representing an increase of 6 FTEs compared to the previous year. 232 employees work with research, compared to 229 last year, 165 employees work in Patient Support & Community Activities, against 161 last year, and 102 employees work with information and communications, against 105 last year. 91 employees are engaged in fundraising activities, against 89 last year, and 62 employees work with administration, which is the same as the year before. Management of foundations The revaluation reserve (note 19) amounts to DKK 64.0m. In 2008, the Danish Cancer Society established a revaluation fund, under which the Society’s rental properties at Strandboulevarden in Copenhagen’s Østerbro district were written up by DKK 108.0m. In 2010, DKK 44.0m of this revaluation were reversed in consequence of a decline in the property assessment value and uncertainty relating to the future tenancy. Grants for scientific work provided, but not yet used (note 21) amounts to DKK 195.4m. The amount comprises grants provided for multi-year research projects which will be paid out as and when the projects are implemented. The Danish Cancer Society manages seven independent foundations whose profits accrue to the Danish Cancer Society in accordance with the charters’ stipulations. At the end of 2012, the capital value of these foundations was DKK 213.8m, against DKK 208.6m last year. The foundations’ returns, amounting to DKK 5.9m in 2011, are recognised in the accounts under “Funds collected”. The asset management departments of Danish banks manage a number of funds held on trust for interest payment to legatees. The capital of these trust funds was computed to be DKK 54.9m at the end of 2011. When the interest payments cease, the capital will accrue to the Danish Cancer Society in whole or in part. 47 Danish Cancer Society | Annual Report 2012 Outlook for 2013 The Danish Cancer Society’s forecast for 2013 is a modest decline in income compared to 2012, when gross income amounted to DKK 764.8m, which was up DKK 121.7m compared to 2011. An important reason for this is the changed prerequisites for the large new fundraising campaign, Beat Cancer, developed in cooperation with TV2 and aired on TV2 throughout week 43, culminating in a gala fundraiser show. This new initiative was the primary reason for the substantial growth in overall income in 2012. However, the Beat Cancer campaign is not expected to reach the same high level of income in 2013, as the campaign will probably be subject to restrictions on the daily amount which may be donated by text messaging. And this will have a decisive impact on the result. Some uncertainty is still expected, particularly in relation to legacy income, which is the Society’s largest source of income. However, based on the small increase in proceeds per inheritance case in 2012, the total legacy income is expected to increase slightly in 2013. As a large part of the membership fee increase was already implemented in 2012, only a minor increase in membership income is expected in 2013. At the same time, a targeted effort aimed at enhancing loyalty and minimising membership decline will be launched, and the intensive member recruitment efforts will be continued as the target of 500,000 members has yet to be reached. In 2012, the profit from the lotteries increased by DKK 10m, among other things due to the Beat Cancer campaign which placed extraordinary focus on the Danish 48 Cancer Society’s November lottery. The performance of the individual lotteries throughout the year can fluctuate greatly, and the chances of maintaining the same high performance in 2013 are consequently subject to some uncertainty. Out of the operating fund, reserves have been allocated for Beat Cancer funds of DKK 50.0m that have not yet been distributed. Similarly, reserves have been allocated for the funding of strategic initiatives in the amount of DKK 26.7m which has not yet been disbursed. An increase in corporate income is expected in 2013, as an intensive effort will be made in particular to develop the corporate involvement in the Beat Cancer campaign into larger and long-lasting partnerships. The corporate income related to Beat Cancer is included in the financial statements of the Beat Cancer campaign. One aim of the value adjustment fund is to ensure that capital losses on the securities portfolio do not impede the Society’s planned level of activities. The fund amounted to DKK 133.9m at the end of 2012. In addition, corporate fundraising continues to be developed – focussing on partnerships with respect to major companies and donations with respect to smaller companies. Campaigns and events are often pivotal for such partnerships, and the related corporate income is expected to increase somewhat in 2013. The equity of the Danish Cancer Society The Society’s equity, consisting of the Society’s operating fund, the Beat Cancer reserve, the reserve for strategic initiatives, value adjustment fund and revaluation fund, amounts to DKK 672.7m at the end of 2012, against DKK 592.2m in 2011. The equity thus increased by DKK 80.5m in 2012, following the year’s profit of DKK 27.0m and value adjustments of DKK 53.4m. The profit for the year of DKK 27.0m is transferred to the Operating fund which balances at DKK 398.0m at the end of the 2012. The Operating fund is used for funding the 2013 budget, which balances at DKK 470.9m (see note 15). The revaluation fund amounted to DKK 64.0m at the end of 2012. It is the policy of the Danish Cancer Society that funds earned in one year are to be used in the following year. This results in a time lapse or lag between the receipt of the income and the incurring of the expense, whereby funds are temporarily amassed. Such funds which remain to be used are temporarily invested in securities to obtain a better return for the benefit of the fight against cancer, as mentioned in the section on securities. SIGNATURES BY THE MANAGEMENT AND THE EXECUTIVE COMMITTEE Statement by the management on the Annual Report The Executive Committee and the management have discussed and approved the financial statements for the financial year 1 January – 31 December 2012 for the Danish Cancer Society on the date written below. The financial statements have been presented in accordance with the requirements for the presentation of financial statements stipulated by the Articles of Association and in accordance with generally accepted accounting principles. In our opinion, the financial statements give a true and fair view of the Society’s assets and liabilities and its financial position at 31 December 2012 and of the results of the Society’s activities for the financial year 1 January – 31 December 2012. In our opinion, the management’s review gives a true and fair account of the matters addressed in the review. The financial statements are hereby approved. Copenhagen, 16 April 2013 Management Leif Vestergaard Pedersen Managing Director Executive Committee Frede Olesen Chairman Ester Larsen Vice-chairman Ejnar Pedersen Jan Bjørn Nielsen Michael Vad 49 Danish Cancer Society | Annual Report 2012 INDEPENDENT AUDITORS’ REPORT To the members of the Central Board of the Danish Cancer Society we comply with ethical requirements and plan and conduct our audit to obtain reasonable assurance that the financial statements are free from material misstatement. Statement on the financial statements We have audited the financial statements (pages 51 65) for the Danish Cancer Society for the financial year 1 January – 31 December 2012, comprising accounting policies, income statement, balance sheet and notes. The financial statements have been prepared in accordance with generally accepted accounting policies. The management’s responsibility for the financial statements The management is responsible for the preparation of financial statements giving a true and fair view in accordance with the Danish Financial Statements Act. The management is also responsible for internal controls considered necessary by the management for preparing financial statements that are free from material misstatement, whether due to fraud or error. The auditors’ responsibility It is our responsibility to express our opinion of the financial statements on the basis of our audit. We have conducted our audit in accordance with international auditing standards and additional requirements in pursuance of Danish auditing legislation and the Executive Order on financial statements and audit of financial statements for recipients of grants from the pools of the Danish Ministry of Finance under the Act on certain games, lotteries and wagers. Those requirements and standards require that 50 An audit includes performing procedures to obtain audit evidence for the amounts and disclosures in the financial statements. The audit procedures selected depend on the assessment made by the auditor, including the assessment of the risk of material misstatement in the financial statements, notwithstanding whether such misstatement is due to fraud or error. In making such risk assessment, the auditor considers internal controls that are relevant to the company’s preparation and fair presentation of financial statements in order to design audit procedures that are appropriate under the circumstances, but not with the objective of expressing an opinion on the efficiency of the internal control made by the company. An audit also includes an assessment of the appropriateness of the accounting policies applied and the accounting estimates made by the management together with an evaluation of the overall presentation of the financial statements. nancial position at 31 December 2012 and of the results of the Society’s activities for the financial year 1 January – 31 December 2012, in accordance with generally accepted accounting principles. Statement on the management’s review We have read the management’s review and the financial review. We have not performed any further procedures in addition to the audit performed of the financial statements. On this basis, it is our opinion that the information in the management’s review is in accordance with the financial statements. Copenhagen, 16 April 2013 Deloitte Statsautoriseret Revisionsaktieselskab In our view, the audit evidence obtained is sufficient and appropriate to provide a basis for our audit opinion. Our audit has not given rise to any qualification. Opinion In our opinion, the financial statements give a true and fair view of the Society’s assets and liabilities and its fi- Henrik Wellejus state-authorised public accountant Christian Sanderhage state-authorised public accountant Finances ACCOUNTING POLICIES The accounting policies are unchanged compared to last year. The financial statements are presented in accordance with generally accepted accounting principles. Capital income BALANCE SHEET Capital income comprises accrued interest income and expenses, dividends and yields as well as rental income less operating expenses for rental properties. Properties Government grants The financial statements reflect the year’s financial decisions/grants, regardless if they are not realised until subsequent years. Government grants are carried as income at the time of receipt. Buildings designated for rental purposes are valued at acquisition cost plus costs of improvement and revaluations and less depreciation. Buildings are depreciated at an annual rate of 2 percent. Buildings for own activities and their costs of improvement are charged to the income statement in the acquisition year. Expenses INCOME STATEMENT Funds collected Legacies and testamentary bequests are recognised as income upon completion of the final estate inventory and receipt of the legacy or bequest whereas payments received on account are recognised on the balance sheet under the item Legacy amounts on account for later determination. Expenses are accounted for on a normal accruals basis. The expenses are attributed directly to the departments/ activities consuming the funds. Common expenses for operating the premises at Strandboulevarden, IT, etc., are charged to the individual activities in accordance with their consumption. Inventory and laboratory equipment, etc., is charged to the income statement at the time of acquisition. Research grants/multi-year projects Contributions from members and foundations as well as corporate contributions, gifts and grants are recognised as income at the time of realisation. Grants received for specific research projects are recognised as income as and when utilised. Grants for one-year or multi-year research projects are charged to the income statement at the time of granting. Grants provided, but not yet used, at the balance sheet date, are recognised as payables under the item Grants for scientific work not yet used. Properties appropriated by inheritance, which are destined for resale or which are subject to residence rights, etc., are recognised at the original appropriation values. Revaluations are recognised in equity under Revaluation fund. Securities Listed bonds and shares are measured at market value at the end of the financial year. Mortgages, etc., are recognised at an estimated, conservative value. Realised and unrealised capital gains and losses are recognised directly in the value adjustment fund. Extraordinary items Income from collections is recognised when the final collection results are available. Income or expenses not attributable to the Society’s ordinary activities are recognised as extraordinary items. Lotteries, etc. Proceeds from lotteries are recognised as income when the individual games are completed. Sale of materials, etc. is recognised as income at the time of invoicing. 51 Danish Cancer Society | Annual Report 2012 Income statement Note 2012 2011 1 2 505,294 112,293 415,760 98,953 617,587 514,713 -68,294 -65,431 549,293 449,282 11,182 35,641 12,584 28,893 596,116 490,759 -35,483 -16,303 -3,785 -34,550 -19,195 -3,785 540,545 433,229 -278,587 -130,954 -103,955 -240,479 -128,215 -94,446 Expenses for main objectives -513,496 -463,140 Net profit (loss) for the year 27,049 -29,911 (DKK 1,000) Income-generating activities Funds collected Lotteries, recycling, sale of goods, etc. Total income from income-generating activities Expenses for the Fundraising & Membership Department’s regular and project activities 3 Profit from income-generating activities Other ordinary income Capital income Government grants 4 5 Total net income Administrative expenses Improvement of buildings for own activities Depreciation and amortisation 6 7 12 Profit for distribution for the objectives of the Danish Cancer Society Research Patient Support & Community Activities Information 52 8 9 10 Finances Balance sheet (DKK 1,000) Note 2012 2011 11 12 992 164,940 1,010 167,225 165,932 168,235 83,395 21,585 677,220 160,151 63,842 21,585 702,209 43,936 942,351 831,572 1,108,283 999,807 398,021 50,000 26,752 133,888 64,000 447,724 80,460 64,000 672,661 592,184 207,237 6,533 894 25,600 195,358 191,751 1,362 806 44,272 169,432 435,622 407,623 1,108,283 999,807 Assets Shares in Kræftens Bekæmpelses Forlag ApS Properties Total non-current assets Sundry receivables, pre-paid expenses, etc. Balance with sundry foundations Securities Cash 13 14 Total current assets Total assets Equity and liabilities Operating fund Reserves for Beat Cancer distribution Reserves for strategic initiatives Value adjustment fund Revaluation fund 15 16 17 18 19 Total equity Payable expenses, etc. Balance with sundry foundations Balance with Kræftens Bekæmpelses Forlag ApS Legacy amount on account for later determination Grants for scientific work not yet used Total liabilities Total equity and liabilities 20 21 53 Danish Cancer Society | Annual Report 2012 NOTES TO THE 2012 FINANCIAL STATEMENTS (DKK 1,000) Gross income Direct expenses Profit 2012 Profit 2011 149,379 120,575 96,781 9,072 23,668 3,244 - 149,379 120,575 96,781 9,072 23,668 3,244 150,768 104,120 95,163 6,895 24,599 4,326 402,719 - 402,719 385,871 31,545 87,743 5,875 11,215 25,670 76,528 25,765 - 423 46 377 4,124 119,711 17,136 102,575 29,889 522,430 17,136 505,294 415,760 112,225 18,907 52,760 44,685 14,543 12,371 67,540 4,364 40,389 57,681 3,946 37,326 183,892 71,599 112,293 98,953 NOTE 1 Funds collected Legacies and testamentary bequests Membership fees and contributions from members and private contributors Grants for specific projects Contributions from foundations Corporate Gifts and grants National collections National collections Beat Cancer Breast cancer month (Breast gala and Support for the Breasts) Total funds collected NOTE 2 Lotteries, recycling, sale of goods, etc. Lotteries *) Thrift shops Other events and product sales Total, lotteries, recycling, sale of goods, etc. *) The Beat Cancer lottery is recognised with a net income of DKK 14.8m. In 2012, DKK 21.6m were paid out as winnings and related tax. 54 Finances (DKK 1,000) 2012 2011 18,554 49,740 17,890 47,541 68,294 65,431 7,770 -11,560 11,994 -9,408 -3,790 2,586 -179 6,259 8,939 -47 427 7,120 2,442 9 14,972 9,998 11,182 12,584 17,493 6,249 11,899 18,743 7,146 3,004 35,641 28,893 NOTE 3 Expenses for the Fundraising & Membership Department’s regular and project activities Operation of Department Project expenses (member care, analyses and development of new games and maintenance of existing games) Total expenses for the Fundraising & Membership Department’s regular and project activities NOTE 4 Capital income Rental income Expenses related to operation of rental property Result of rental operations Bank interest income Bond yields Share dividends Other income, etc. Total capital income NOTE 5 Government grants Pools and lottery funds Grants from the regions to the cancer counselling centres Grants from the regions to the Dallund Rehabilitation Centre Total government grants 55 Danish Cancer Society | Annual Report 2012 2012 2011 8,055 8,148 4,300 11,547 3,433 8,066 7,885 4,225 10,729 3,645 35,483 34,550 Improvement of buildings and technical investments, etc. Research premises Office premises Portal project Expenses related to torrential rain storm, net 4,700 4,339 7,030 234 17,545 1,378 272 Improvement of buildings and technical investments, etc. 16,303 19,195 (DKK 1,000) NOTE 6 Administrative expenses Central Board, committees and Management and Policy & Legal Advice Finance and asset management Property management Common staff expenses & HR Canteen Total administrative expenses NOTE 7 56 Finances 2012 2011 71,588 48,488 70,052 46,180 120,076 116,232 1,557 1,597 10,144 7,000 59,673 3,982 15,340 79,150 4,263 14,787 78,995 98,200 Research professorships Palliation and pain Late sequelae Adjustment of grants Research schools 10,000 7,500 7,500 -250 - 5,000 471 Total strategic funds 24,750 5,471 16,951 8,125 4,255 11,234 2,500 75 3,850 4,289 3,765 - Total new strategic funds *) 43,065 11,979 Total research (see note 21) 278,587 240,479 (DKK 1,000) NOTE 8 Research The Danish Cancer Society Research Center Externally funded projects Total, operation of own research departments Research grant administration Quality & Patient Safety Grants from the Danish Cancer Society’s Scientific Committee Grants from the Psychosocial Cancer Research Committee Grants from the Executive Committee and the Central Board (note 8A) Total grants Live Life, main account Live Life, Centre for Intervention Research Symptom and diagnosis, cancer disease diagnostics in Aarhus Rehabilitation, strategic palliation Centre for Integrated Rehabilitation of Cancer Patients NKF – National Research Centre for Rehabilitation *) Including distributions of DKK 30.0m covered by the profit from Beat Cancer. 57 Danish Cancer Society | Annual Report 2012 2012 2011 921 2,779 3,523 2,543 900 1,126 414 1,934 1,200 879 817 5,678 2,502 1,800 1,251 1,092 402 366 - 15,340 14,787 12,038 9,656 49,430 18,525 2,433 4,744 8,393 12,854 9,823 48,347 18,048 4,254 5,322 4,809 Externally funded projects 105,219 13,836 103,457 13,154 Dallund Rehabilitation Centre 119,055 11,899 116,611 11,604 130.954 128.215 (DKK 1,000) NOTE 8A Grants from the Executive Committee and the Central Board Grants for researchers’ participation in congresses, etc. Grants for other projects, etc. Management framework Nordic Cancer Union Intestinal project Central Denmark Region Documentation centre Membership fee, Danish Patients Repayments to the Hejmdal Joint Foundation Research, water damage Regional Chemotherapy, Herlev Total grants from the Executive Committee and the Central Board NOTE 9 Patient Support & Community Activities Patient Support & Community Activities, management Cancer line Cancer Counselling Centres Community volunteering Patients’ associations Patient grants Projects and other activities Total, Patient Support & Community Activities 58 Finances 2012 2011 Information Cancer Prevention & Documentation Communications Volunteering General information through lotteries 29,932 23,175 13,753 2,638 25,983 21,182 11,990 2,359 Externally funded projects 69,498 34,457 61,514 32,932 103,955 94,446 1,010 -18 985 25 992 1,010 (DKK 1,000) NOTE 10 Total information NOTE 11 Shares in Kræftens Bekæmpelses Forlag ApS Balance, 1 January Net profit for the year Balance, 31 December (The Society holds all shares) 59 Danish Cancer Society | Annual Report 2012 2012 2011 Rental properties Acquisition price, 1 January Disposals 142,276 - 142,276 - Acquisition price, 31 December 142,276 142,276 Revaluation, 1 January Disposals 64,000 - 64,000 - Revaluation, 31 December 64,000 64,000 Depreciation, 1 January Depreciation for the year -44,847 -3,785 -41,062 -3,785 Depreciation, 31 December -48,632 -44,847 157,644 161,429 Properties appropriated by inheritance, subject to residence rights, etc. Balance, 1 January Additions during the year Disposals during the year 5,796 1,500 - 12,609 -6,813 Balance at 31 December 7,296 5,796 164,940 167,225 (DKK 1,000) NOTE 12 Balance, 31 December (Property valuation as at 1 October 2011: DKK 283,596,000) (Property valuation as at 1 October 2011: DKK 8,833,000) Total properties Properties utilised for own activities are charged to income in the acquisition year. As at 1 October 2011, the public land-assessment value of these properties is DKK 278,404,000. Settlements, etc. Properties subject to lifelong residence rights and special obligations of use are carried as assets under “Properties” at the amount of DKK 7.293,000. 60 Finances 2012 2011 2,705 4,158 76,532 2,547 4,264 57,031 83,395 63,842 Securities Bonds Shares Mortgages, etc. 545,815 128,205 3,200 526,100 172,909 3,200 Total securities 677,220 702,209 (DKK 1,000) NOTE 13 Sundry receivables, pre-paid expenses, etc. Accrued bond yield Deposits concerning leases Receivables and pre-paid expenses Total sundry receivables, pre-paid expenses, etc. NOTE 14 61 Danish Cancer Society | Annual Report 2012 2012 2011 447,724 27,049 -50,000 -26,752 477,635 -29,911 - 398,021 447,724 Breakdown of the operating fund Approved 2013 expenditure budget: Research Strategic funds Patient Support & Community Activities Information Administration and shared staff expenses Used for construction and building works and building depreciation, etc. 163,461 28,758 95,943 65,027 42,326 5,750 % 41 7 24 16 11 1 2013 expenditure budget for the Fundraising & Membership Department 401,265 69,681 (DKK 1,000) NOTE 15 Operating fund Balance, 1 January Net profit for the year Reserves for Beat Cancer Reserves for strategic initiatives Balance, 31 December 100 470,946 Covered by income in 2013 -72,925 398,021 NOTE 16 Reserves for Beat Cancer distribution Beat Cancer profit 2012 Distributed during the year 62 91,317 -41,317 - 50,000 - Finances 2012 2011 Reserves for strategic initiatives Provisions Used in previous years Distributed during the year 90,000 -20,183 -43,065 - Balance, 31 December 26,752 - 80,460 35,077 19,678 -1,340 13 94,341 7,421 -21,379 -388 465 133,888 80,460 64,000 - 64,000 - 64,000 64,000 (DKK 1,000) NOTE 17 NOTE 18 Value adjustment fund Balance, 1 January Value adjustment, bonds Value adjustment, shares Value adjustment, currency Value adjustment, properties appropriated by inheritance Balance, 31 December NOTE 19 Revaluation fund Balance, 1 January Write-downs of rental properties Total revaluation fund 63 Danish Cancer Society | Annual Report 2012 2012 2011 958 31,194 1,378 38,664 135,043 1,306 31,645 1,340 41,126 116,334 207,237 191,751 Grants for scientific work not yet used Balance, 1 January Granted during the year from the scientific committees, the Executive Committee and the Central Board (see note 8) Distributed during the year 169,432 278,587 -252,661 173,801 240,479 -244,848 Balance as at 31 December for use in 2013 and later 195,358 169,432 157,245 20,643 17,470 122,193 31,039 16,200 195,358 169,432 (DKK 1,000) NOTE 20 Payable expenses, etc. A tax, etc. payable Calculated holiday pay obligations Deposits and pre-paid rent Accounts payable Received grants from providers of external funds not yet used Total payable expenses etc. NOTE 21 The grants have been given for use in 2013 2014 2015 and later 64 Økonomi 2012 2011 285,175 41,554 1,327 275,674 39,838 1,315 328,056 316,827 Representation of this amount in the financial statements Wages and salaries for research, patient support & community activities, information and administration Wages and salaries for income-generating activities 260,042 45,372 251,093 43,040 Total wages and salaries 305,414 294,133 22,642 22,694 328,056 316,827 652 646 (DKK 1,000) (Notes not referred to in the financial statements) Breakdown of the total amount for staff wages, etc. Wages and salaries *) Contributions for pension-related purposes Share of expenses for social security Total *) No fee has been paid to the Presidium, Central Board and Executive Committee. Wages and salaries included in grants used Total wages and salaries paid out Average number of employees Contingent liabilities The Danish Cancer Society has granted a deficit guarantee of up to DKK 1.5m a year. The liability is effective for a period of 10 years. 65 Danish Cancer Society | Annual Report 2012 Management, committees and organisation The Presidium •P resident: Professor Linda Nielsen •V ice-president: Per Larsen, special advisor, former assistant commissioner •V ice-president, Jes Dorph-Petersen, reporter/TV presenter The Executive Committee •C hairman: Professor Frede Olesen, MD •V ice-chairman: Ester Larsen, MA, former minister of health • J an Bjørn Nielsen, consultant doctor • E jnar Pedersen, former chief municipal executive •M ichael Vad, managing director The Central Board •C hairman: Professor Frede Olesen, MD, Århus •V ice-chairman: Ester Larsen, former minister of health, Kerteminde •B irgitt Bjerre, courier, Nykøbing F •A lice Skjold Braae, former purchasing manager, Fårevejle •C laus Foged, architect, Hjørring •S øren Gade, managing director, Holstebro •H ans Grishauge, head of secretariat, Copenhagen •M ai-Britt Guldin, psychologist, PhD, Egå •H enrik Harling, chief consultant doctor, MD, Holte •B irthe Harritz, adult supervisor and local councillor, Tjele •H elle Ibsen, GP, Haderslev •N iels Them Kjær, project manager (staff representative) •C harlotte Fabricius Kragh, MSc (nursing), associate professor, nurse, Kirke Eskildstrup •G rethe Kristine Kristensen, nurse, Vojens •O rla Kastrup Kristensen, farm owner, Aars 66 •S usanne Ursula Larsen, consultant doctor, Odense • Jan Bjørn Nielsen, consultant doctor, Odder • J ørgen Nielsen, attorney-at-law, Dronninglund • E jnar Pedersen, former chief municipal executive, Hornslet •R onni Sølvhøj Pedersen, PhD student, Copenhagen •T ove Pedersen, chair of local unit, Vodskov •C harlotte Scheppan, Director, Odense •N adja Brøndsted Sejersen, MA student (sociology), Copenhagen • Lisa Sengeløv, head consultant doctor, MD, Copenhagen • Anette Sloth, managing senior nurse, Thisted •H enrik Steenberg, human resources associate, Copenhagen •A nne Tjønneland, head of department, consultant doctor, PhD, MD (staff representative) • Michael Vad, managing director, Hellerup • Lisbeth Winther, city council member, Gentofte • Gina Øbakke, former mayor, adult education teacher, Rødvig Stevns Board of Management • Leif Vestergaard Pedersen, managing director • Hans Henrik Storm, head of department • Jørgen H. Olsen, research director • Laila Walther, head of department Executive Group • Kurt Damsgaard, communications manager • Charlotte Dehlie, HR manager • Bjarne Heide Jørgensen, head of department • Thomas Norling Kielgast, financial director and administrative manager • Janne Lehmann Knudsen, quality manager • Poul Møller, fundraising manager • Jørgen H. Olsen, research director • Leif Vestergaard Pedersen, managing director • Hans Henrik Storm, head of department • Laila Walther, head of department • Una Jensen Hallenberg, head of department The Danish Cancer Society’s Scientific Committee • Chairman: Professor Henrik Ditzel, MD, consultant doctor, University of Southern Denmark • Vice-chairman: Professor Cai Grau, MD, consultant doctor, Aarhus University Hospital • Professor Michael Baumann, MD, director, National Center for Radiation Research in Oncology, Dresden • Professor, Michael Borre, MD, PhD, Aarhus University Hospital, Skejby • Professor Marianne Ewertz, MD, consultant doctor, Odense University Hospital • Professor Sten L. Christer Höög, PhD, Karolinska Institute, Stockholm • Professor Klas Kärre, MD, PhD, Department of Microbiology, Tumor and Cell Biology (MTC), Stockholm • Ulrik Lassen, MSc Medicine, PhD, consultant doctor, Finsen Centre, Rigshospitalet • Professor Jiri Lukas, DVM, PhD, managing director, University of Copenhagen • Professor Anders Henrik Lund, PhD, University of Copenhagen • Professor Elsebeth Lynge, MSc (soc.), University of Copenhagen • Professor Gillian Murphy, PhD, Department of Oncology, Cambridge University • Professor Kim Overvad, consultant doctor, PhD, Aarhus University • Professor Sven Påhlman, University Hospital MAS, Malmö • Henrik Sengeløv, MD, consultant doctor, Rigshospitalet Management, committees and organisation Psychosocial Research Committee Local Units Committee • Chairman: Signe Vikkelsø, associate professor, MSc (psychology), PhD, Copenhagen Business School • Vice-chairman: Professor Lene Koch, D Phil., University of Copenhagen • Niels Viggo Hansen, MA, PhD, centre manager, University of Copenhagen • Professor Marianne Jensen Hjermstad, PhD, Oslo University Hospital • Marianne Lau, MD, consultant doctor, Stolpegård Psychotherapeutic Centre in Gentofte • Susanne Dalsgaard Reventlow, MD, GP, MSc (anthropology), research manager, associate honorary professor, University of Copenhagen • Professor Per Sjøgren, consultant doctor, MD, Rigshospitalet • Professor Jens Søndergaard, PhD, University of Southern Denmark • Professor Tine Tjørnhøj-Thomsen, PhD, MSc (anthropology), University of Copenhagen • Chairman: Henrik Frostholm, special consultant • Ole Peter Andersen, local unit chairman • Ejner Frøkjær, local unit chairman • Connie Yilmaz Jantzen, centre manager • Anne Kjaer, policy and strategy consultant • Ulla Solvang, relaxation teacher • Birgitte Uldall, local unit chairman Patient Support Committee • Chairman: Ida Sofie Jensen, group CEO • Marie-Helene Olsen, managing senior nurse • Ulla Svendsen, manager • Mikael Kristensen, medical executive • Tina Brændgaard, MA • Anders Korsgaard Christensen, head psychologist • Margit Maltesen, GP • Dorthe Crüger, medical executive Prevention and Information Committee • Chairman: Professor Bente Klarlund Pedersen, MD, consultant doctor, Rigshospitalet • Vice-chairman: Suzanne Aaholm, hospital director, Hillerød Hospital • Professor Gert Almind, MD • Troels Borring, chairman, Danish association of residential continuation schools • Peter Bork, managing director, Provendo ApS • Professor Bjarne Ibsen, research and centre manager, University of Southern Denmark • Jes Søgaard, MA (social science) • Lizette Risgaard, vice-president of the Danish Confederation of Trade Unions 67 Danish Cancer Society | Annual Report 2012 Research – Grant holders Aarhus, Rikke Adamsen, Lis Alsner, Jan Andersen, Anni Hangaard Andersen, Claus Lindbjerg Andersen, Lars Dyrskjøt Andersen, Mads Hald Andreasen, Peter André Assenholt, Jannie Bartek, Jiri Beierholm, Anders Ravnsborg Blaakær, Jan Borre, Michael Brünner, Nils Buus, Christian Bøtkjær, Kenneth Alrø Chakera, Annette Hougaard Christensen, Camilla Laulund Christensen, Lisbeth Lydiksen Christensen, Marianne Skovgaard Christoffersen, Nanna Rønbjerg Clausen, Rasmus Prætorius Clemmensen, Knut Kristoffer Bundgaard Cour, Karen la Danielsen, Allan Vestergaard Daugaard, Gedske Ditzel, Henrik Jørn Drzewiecki, Krzysztof Tadeusz Ebbesen, Maria Schou Ehlers-Hansen, Charlotte Erler, Janine Ewald, Jesper Dupont Falk, Sarah Friis, Søren Gaist, David Gajhede, Michael Geisler, Christian Harmann Golas, Mariola Monika 68 160 179 173 1 51 93 50 2 52 3 53 183 92 54 129 4 94 55 131 5,6 7 8 130 180 132 174 95 56 133 134 58 135 9 121 122 10 96 11 Graungaard, Anette Hauskov 161 Groth, Anja 12 Grum-Schwensen, Birgitte 13 Grønbæk, Kirsten 57 Grønbæk, Morten 177 Grønvold, Mogens 97, 176 Gupta, Ramneek 59 Hadrup, Sine Reker 60 Hansen, Karina Kiilerich 14 Hansen, Klaus 15 Hansen, Niels Viggo 162 Hansen, Steen Henning 16 Hansen, Stine Ninel 61 Hartmann, Rune 17 Helin, Kristian 18 Hellwege, Sofie 136 Henriksen, Nina 163 Hickson, Ian David 19 Hjalgrim, Henrik 118 Hokland, Peter 62 Holmgaard, Rikke Bæk 63 Horsman, Michael Robert 20 98 Hutchings, Martin Høeberg, Mikkel 64 Høyer, Morten 65 138 Idorn, Manja Illemann, Martin 21 22 Issinger, Olaf-Georg Jakobsen, Lis 23 Jakobsen, Merete Demant 164 Jensen, Anders Bonde 182 25 Jensen, Kim Bak Jensen, Niels Frank 66 Jensen, Torben Heick 26 Jepsen, Lene Østergaard 165 Joensen, Eydbjørg Gaard 139 Johansen, Christoffer 186 Johansen, Julia Sidenius 67 24 Jäättelä, Marja Helena Kallunki, Tuula Anneli 27 99 Kehlet, Henrik Khadem, Talie Alsadat Hadi 137 Kielsen, Katrine 140 Kjær, Andreas 100 Klitkou, Jakob 141 Knox, Jeanette Bresson Ladegaard 166 Krejsgaard, Thorbjørn Frej 28 29 Kriegbaum, Mette Camilla Kristensen, Stine Bjørn 142 68 Lassen, Ulrik Laurberg, Søren 101, 175 69 Laurberg, Tinne 30 Lukanidin, Eugene 31 Lukas, Jiri Lund, Anders Henrik 32 Lundqvist, Johan 33 Mailand, Niels 34 Mandrup, Karen Riiber 35 Mayorca, Alejandro E. 36 Melbye, Mads 88 70 Mellemgaard, Anders Meyts, Ewa Rajpert-De 71 Mikkelsen, Marianne 37 Mirza, Mansoor Raza 102 Mischorr-Boch, Christina Vigel 169 Mohammad, Ladan Ghulam 143 Mortensen, Michael Bau 103, 184 Mosbech, Christiane 144 Hammershaimb Myer, Toshis 38 Müller, Klaus Gottlob 104 Møller, Johanne Rask 145 Møller, Lisbeth Birk 39 Mørch, Lina Steinrud 123 Neergaard, Mette Asbjørn 182 Nielsen, Claus Vinther 124 Nielsen, Dorte Lisbet 105 Nielsen, Mads 89 Nielsen, Nikolaj 40 Nielsen, Olaf 41 Nilbert, Mef 119 Obling, Anne Roelsgaard 167 Oest, Anders 146 Offersen, Birgitte 106 Olsen, Jørn 125 Olsen, Sidsel Bering 147 Osler, Merete 171 Ostenfeld, Marie Stampe 72 Ottesen, Bent 168 Overgaard, Jens 107 Palner, Mikael 42 Pedersen, Astrid Munk 148 Pedersen, Bjørn Panyella 43, 44 Pedersen, Lotte Bang 45 149 Pedersen, Tina Gerbek Petersen, Lone Kjeld 108 Poulsen, Hans Skovgaard 73 Poulsen, Marie Louise Mølgaard 74 Poulsen, Per Rugård 75 Poulsen, Thomas Bjørnskov 46 76 Ralfkiaer, Elisabeth 109 Rosenschöld, Per Munck af Rottmann, Nina 126 150 Rudkjøbing, Laura Aviaja Rugbjerg, Katrine 127 Rødsten, Kirstine 151 Salanti, Ali 47 Sandelin, Albin 77 Schmidt, Henrik 110 Schmiegelow, Kjeld 111 Schrøder, Henrik 112 Schüz, Joachim 90 Sengeløv, Henrik 113 Sindrup, Søren Hein 78 Sisman, Yagmur 152 Sjøgren, Per 181, 185 Skyt, Peter Sandegaard 79 Sperling, Cecilie 170 114 Svane, Inge Marie Svendsen, Lars Bo 187 Søes, Signe 153 Søgaard, Alexandra 80 Sørensen, Anders Lindholm 154 Sørensen, Boe Sandahl 115 Sørensen, Brita Singers 81 Sørensen, Claus Storgaard 48 155 Sørensen, Eva Futtrup Sørensen, Karian Dalsgaard 82 83 Sørensen, Morten Dræby 84 Sørensen, Tine Thurison 116 Tanderup, Kari Thorn, Sofie 156 157 Tjørring, Julie Mie 158 Tolstrup, Rikke 172, 178 Vedsted, Peter 128 Vestergaard, Mogens 85 Vindeløv, Lars Lindhardt Vinten, Ea Rebekka 159 Wewer, Ulla Margrethe 49 Wille-Jørgensen, Peer Anders 117 Winther, Jeanette Falck 120 91 Wiuf, Carsten Zachariae, Bobby 174 86 Ødum, Niels Feentved 87 Ørntoft, Torben Falck Grants Grants from The Danish Cancer Society's Scientific Committee (KBVU) NB: The list contains projects in progress in 2013 which were granted support in 2012 or earlier, as well as projects granted support in 2012 for use in 2012. * G rants awarded prior to 2012 and charged to the income statement in previous financial statements. £ rants for research projects being conducted G at the Danish Cancer Society’s own research departments. Grants for research projects being conducted at other research departments. Basic research *1. Improved cancer therapy with epidophyllotoxins, anthracyclines and camptothecins by inactivating specific DNA repair factors. Anni Hangaard Andersen, lic. scient., PhD, associate professor Department of Molecular Biology, Aarhus University Granted for 2011-2013: DKK 1,350,000 2. Inhibition of the tumour-biological functions of matriptase. Professor Peter André Andreasen, DSc Department of Molecular Biology and Genetics, Aarhus University Granted for 2013-2015: DKK 2,250,000 *£3. Maintaining genome integrity and its influence on tumour formation and the effect of cancer therapy. Jiri Bartek, PhD, head of department Genome integrity, Danish Cancer Society Research Center Granted for 2013-2015: DKK 4,740,000 *4. New methods for targeting cancer metastasis: Development of therapeutic inhibitors against protein-degrading enzymes. Kenneth Alrø Bøtkjær, MSc Cambridge Cancer Research Institute, Cambridge University, UK Granted for 2012-2014: DKK 1,800,000 5. Development of cancer therapy targeted against members of the DNA polymerase ß super family. Marianne Skovgaard Christensen, MSc, PhD Sir William Dunn School of Pathology, UK Granted for 2013-2014: DKK 1,298,100 6. Development of cancer therapy targeting members of the DNA polymerase ß super family. Marianne Skovgaard Christensen, MSc, PhD Period of study at Sir William Dunn School of Pathology, UK Granted for 2013-2015: DKK 81,514 *7. Cellular control mechanisms for microRNA-mediated regulation of gene expression in cancer. Nanna Rønbjerg Christoffersen, MSc, PhD Biotech Research and Innovation Centre (BRIC), University of Copenhagen Granted for 2011-2013: DKK 1,800,000 *8. Development of lysine histone demethylase inhibitors for epigenetic prostate cancer therapy – a new pharmacological tool. Rasmus Prætorius Clausen, MSc, PhD, associate professor Department of Medicinal Chemistry, University of Copenhagen Granted for 2011-2013: DKK 1,200,000 9. Cancer pain signalling – investigating the role of the P2X7 receptor in pain development. Sarah Falk, MSc Study visit at Department of Neuroscience, Physiology and Pharmacology, England Granted for 2012-2013: DKK 29,400 *10. Identification of molecules that are potential medicines targeting the suspected breast-cancer oncogene KDM5B. Professor Michael Gajhede, MSc, PhD Department of Medicinal Chemistry, University of Copenhagen Granted for 2012-2013: DKK 1,200,000 *11. Identification of molecular mechanisms responsible for development of highly aggressive brain cancer in children. Mariola Monika Golas, MSc Medicine, MSc, PhD Department of Anatomy, Aarhus University Granted for 2012-2014: DKK 1,350,000 *12. The implications of replication stress for epigenetic cellular changes and cancer development. Anja Groth, MSc, PhD, associate professor Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2012-2014: DKK 2,250,000 *£13. Blocking tumour-promoting immune cells to inhibit the metastasis of primary tumours. Birgitte Grum-Schwensen, MSc, PhD Department of Tumour Microenvironment and Metastasis, Institute of Cancer Biology, Danish Cancer Society Granted for 2012-2013: DKK 1,200,000 14. GPCR signalling pathways in breast cancer metastasis. Karina Kiilerich Hansen, MSc, PhD NIDCR, National Institutes of Health, USA Granted for 2013-2014: DKK 1,200,000 *15. Identification and characterisation of new recruitment proteins for polycomb proteins and their role in cell specification and cancer. Klaus Hansen, MSc, PhD, associate professor Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2012-2014: DKK 1,800,000 *16. Characterisation of a new mechanism for the tumour-suppressor function of the cell-cell adhesion molecule E-cadherin. Steen Henning Hansen, MD Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2012-2014: DKK 1,800,000 *17. Interferon lambda in cancer development and chronic viral infections. Rune Hartmann, PhD, associate professor Centre for Structural Biology, Aarhus University Granted for 2011-2013: DKK 1,200,000 *18. Function of the TET2 protein in haematopoiesis and cancer. Professor Kristian Helin, PhD, director Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2012-2014: DKK 6,000,000 *19. Identification of the role of the PICH protein, a presumed tumour suppressor, in the maintenance of chromosome stability. Professor Ian David Hickson, PhD Department of Cellular and Molecular Medicine, University of Copenhagen Granted for 2011-2013: DKK 4,200,000 69 Danish Cancer Society | Annual Report 2012 *20. Identification and targeted treatment of microenvironment and vascular factors in tumours with a view to enhancing the effect of radiation therapy. Michael Robert Horsman, PhD, MD, associate professor Department of Experimental Clinical Oncology, Aarhus Hospital Granted for 2012-2014: DKK 1,350,000 21. Characterisation of different growth patterns in hepatic metastases: gene-expression profiling and the implications of the extracellular matrix. Martin Illemann, MSc (Engineering), PhD Study visit at McGill University Health Center, Canada Granted for 2012-2013: DKK 38,160 *22. CK2, a druggable kinase – Investigation of the function and regulation of multiple signalling pathways in human cancers under normoxia and hypoxia. Professor Olaf-Georg Issinger, Dr.rer.nat.habil. Department of Biochemistry and Molecular Biology, University of Southern Denmark Granted for 2011-2013: DKK 1,950,000 *23. Functional analysis of new centrosomal proteins for investigating the importance of centrosome cycles in cancer development. Lis Jakobsen, MSc, PhD Department of Biochemistry and Molecular Biology, University of Southern Denmark Granted for 2012-2013: DKK 1,200,000 *£24. Regulation of autophagy – a future strategy for cancer therapy. Professor Marja Helena Jäättelä, MD Apoptosis Laboratory, Institute of Cancer Biology, Danish Cancer Society Granted for 2012-2014: DKK 4,500,000 70 25. Stem cells and intestinal cancer – a new diagnostic tool. Kim Bak Jensen, MSc, PhD, team leader Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2013-2015: DKK 2,400,000 26. Connections betwen non-coding RNA, the nuclear exosome and cancer. Professor Torben Heick Jensen, PhD Department of Molecular Biology and Genetics, Aarhus University Granted for 2013-2015: DKK 2,250,000 *£31. Structure and function of molecular mechanisms regulating the genotoxic stress-induced anti-cancer barrier. Jiri Lukas, DVM, PhD, Centre Director Novo Nordisk Foundation Centre for Protein Research, University of Copenhagen Granted for 2011-2013: DKK 4,500,000 32. Identification and analysis of cancerrelated non-coding RNA molecules. Professor Anders Henrik Lund, MSc, PhD Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2013-2015: DKK 2,500,000 *37. Therapeutic vaccine against chronic hepatitis C virus infection. Marianne Mikkelsen, MSc, PhD Department of Infectious Diseases, Hvidovre University Hospital Granted for 2012-2013: DKK 400,000 *38. The importance of histone demethylases in UV-induced DNA damage in Caenorhabditis elegans. Toshia Myer, PhD Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2011-2013: DKK 1,800,000 £27.Analysis of new regulators of ErbB2-induced cell invasion. Tuula Anneli Kallunki, DSc, PhD, team leader Cell death and metabolism, Danish Cancer Society Research Center Granted for 2013-2015: DKK 1,650,000 33. Molecular mechanisms in vitamin D-induced regulation of aromatase. Johan Lundqvist, PhD pharm. Study visit at Stanford University, USA Granted for 2012-2013: DKK 41,400 28. The role of bacterial toxins in development of colon cancer. Thorbjørn Frej Krejsgaard, MSc, PhD Department of International Health, Immunology and Microbiology, University of Copenhagen Granted for 2013: DKK 600,000 34. Molecular regulation of translesion DNA synthesis, a double-edged sword for cancer development. Professor Niels Mailand, PhD Novo Nordisk Foundation Centre for Protein Research, University of Copenhagen Granted for 2013-2015: DKK 2,250,000 *29. Studies comprising function and expression of the structural homologues C4.4A and Haldisin in benign and malignant skin lesions. Mette Camilla Kriegbaum, MSc Finsen Laboratory, Rigshospitalet Granted for 2012-2014: DKK 1,350,000 35. Development of methods for risk assessment of xenobiotic chemicals’ influence on the onset of breast cancer. Karen Riiber Mandrup, MSc Veterinary Medicine Study visit at Fox Chase Cancer Center, USA Granted for 2012: DKK 28,300 *£30. The organ-micro environment for development of cancer metastases. Professor Eugene Lukanidin, MD, DSc. Department of Molecular Cancer Biology, Institute of Cancer Biology, Danish Cancer Society Granted for 2010-2012: DKK 900,000 36. Prevention of lymphatic metastases by recreating homeostasis in the stroma of lymph nodes. Alejandro E. Mayorca, MSc Dental Science. Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2013-2015: DKK 1,800,000 39. Primary cilia and signalling in Tuberous Sclerosis Complex. Lisbeth Birk Møller, MSc, PhD, senior researcher Kennedy Centre, Capital Region of Denmark Granted for 2013-2015: DKK 1,650,000 40. Function of ion transport proteins in pancreatic stellate cells. Nikolaj Nielsen, MSc Study visit at Institute of Physiology II, Westfälische Wilhelms-Universität Münster, Germany Granted for 2012-2013: DKK 10,000 *41. Genome stability mediated by Ddb1-Cul4-Cdt2 ubiquitin ligase. Professor Olaf Nielsen, MSc, PhD Department of Biology, University of Copenhagen Granted for 2012-2013: DKK 450,000 *42. In vivo fluorescent imaging of specific cancer types. Mikael Palner, MSc Department of Radiology, Stanford School of Medicine, USA Granted for 2012-2014: DKK 1,800,000 Grants *43. Characterisation of the Ptch1/Shh complex: structure and functional implications. Bjørn Panyella Pedersen, MSc, PhD Molecular Structure Group, University of California, USA Granted for 2011-2013: DKK 1,800,000 *44. Characterisation of the Ptch1/Shh complex: structure and functional implications. Bjørn Panyella Pedersen, MSc, PhD Scholarly visit to Molecular Structure Group, University of California, USA Granted for 2011-2014: DKK 232,100 45. Transport of PDgFR alpha to the primary cilium. Lotte Bang Pedersen, MSc, PhD, associate professor Department of Biology, University of Copenhagen Granted for 2013: DKK 259,000 Claus Storgaard Sørensen, MSc, PhD, associate professor Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2012-2014: DKK 1,800,000 *49. Enzymes, including proteases and kinases, and their key function in cancer invasion. Professor Ulla Margrethe Wewer, MD Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2012-2014: DKK 1,950,000 Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements: DKK 25,825,874 * Granted before 2012 and charged to the income statement in previous financial statements. Basic and clinical research *46. Mechanistic investigation of rakicidin A – a new hypoxia-selective anti-cancer natural substance. Thomas Bjørnskov Poulsen, MSc, PhD Department of Chemistry, Aarhus University Granted for 2012-2014: DKK 900,000 *50. Attacking immunosuppressed proteins: a new cancer vaccine strategy. Professor Mads Hald Andersen, civil engineer, DTechn, PhD Centre for Cancer Immune Therapy (CCIT), Herlev Hospital Granted for 2011-2013: DKK 1,800,000 47. Malaria proteins in cancer therapy and diagnostics. Ali Salanti, MSc, PhD, associate professor Department of International Health, Immunology and Microbiology, University of Copenhagen Granted for 2013: DKK 750,000 *51. Cancer-specific genomic rearrangements, a basis for personalised treatment of colorectal cancer. Claus Lindbjerg Andersen, PhD, associate professor Clinical Institute, Skejby Hospital Granted for 2012-2014: DKK 1,650,000 *48. New role for the breast cancer proteins BRCA2 and PALB2 in the DNA damage response. 52. Cancer-specific 3’UTR alterations in colorectal cancer consequences, mechanism and potential clinical implications. Jannie Assenholt, MSc, PhD Department of Clinical Medicine, Aarhus University Granted for 2013-2014: DKK 1,200,000 *53. Tissue-equivalent, time-resolved dose verification of advanced radiation therapy. Anders Ravnsborg Beierholm, MSc Radiation Therapy, Herlev Hospital Granted for 2012-2013: DKK 1,200,000 *54. An innovative approach to individual-based treatment of metastatic colorectal cancer. Professor Nils Brünner, MD Department of Veterinary Disease Biology, University of Copenhagen Granted for 2011-2013: DKK 1,250,000 55. Establishment of murine transgene small-cell lung cancer models for identification and testing of new treatment goals. Camilla Laulund Christensen, MSc Medical Oncology, Dana-Farber Cancer Institute, USA Granted for 2013-2014: DKK 1,279,300 *56. Lipofilling with MSC-enriched fat tissue, a permanent autologous filler? Professor Krzysztof Tadeusz Drzewiecki, MD Department of Plastic Surgery, Breast Surgery and Burns Treatment, Rigshospitalet Granted for 2012-2013: DKK 900,000 57. Causes of DNA hypermethylation in haematological cancer. Kirsten Grønbæk, MD, consultant Department of Haematology, Finsen Centre, Rigshospitalet Granted for 2013-2015: DKK 1,800,000 58. Tumour endothelial marker 8 (TEM8) as target for blocking tumour growth. Janine Erler, MSc, PhD, team leader Biotech Research & Innovation Centre (BRIC), University of Copenhagen Granted for 2013-2015: DKK 3,050,000 *59. The importance of genetic polymorphisms for long-term sequelae after testicular cancer therapy. Ramneek Gupta, MSc, PhD Department of Systems Biology, Technical University of Denmark Granted for 2012-2014: DKK 1,800,000 *60. Unravelling T-cell immunity directed at Merkel Cell Polyomavirus. Sine Reker Hadrup, MSc, PhD Centre for Cancer Immune Therapy (CCIT), Herlev Hospital Granted for 2011-2013: DKK 1,360,000 61. Identification and early validation of biomarkers for docetaxel – sensitivity in breast cancer. Stine Ninel Hansen, MSc Study visit at Ontario Institute for Cancer Research, Canada Granted for 2012: DKK 22,230 *62. Can the hMICL protein be the link between the paradigms of leukemic stem cells and minimal residual disease – myeloid leukemias as a model system. Professor Peter Hokland, MD Clinical Institute, Aarhus Hospital Granted for 2012-2014: DKK 1,500,000 63. Blocking the immunosuppresant proteins CTLA-4 and IDO in cancer. Rikke Bæk Holmgaard, MSc, PhD Memorial Sloan-Kettering Cancer Center, USA Granted for 2013-2014: DKK 1,200,000 71 Danish Cancer Society | Annual Report 2012 64. Identification and characterization of new membrane-localized TIMP-1 interaction partners. Mikkel Høeberg, MSc Study visit at Beijing Institute and Genomics, Chinese Academy of Sciences, China Granted for 2013: DKK 25,200 65. Biologically optimised stereotactical radiation therapy of hepatic tumours. Professor Morten Høyer, MSc Medicine, PhD Department of Oncology, Aarhus University Hospital Granted for 2013-2015: DKK 1,690,000 66. Molecular mechanisms for resistance to oxaliplatin or irinotecan in human colon cancer cell lines. Niels Frank Jensen, MSc Study visit at National Cancer Institute, National Institutes of Health, USA Granted for 2012: DKK 27,700 *67. Identification of microRNA in serum and tissue as biomarkers of early diagnosis, treatment response and prognosis in pancreatic cancer patients. Professor Julia Sidenius Johansen, MSc Medicine, MD Department of Oncology, Herlev Hospital Granted for 2012-2013: DKK 1,400,000 *68. In vivo metabolism and growthinhibiting trials with specific tyrosine kinase inhibitors in glioblastoma multiforme Ulrik Lassen, MSc Medicine, consultant Finsen Centre, Rigshospitalet Granted for 2012-2014: DKK 1,800,000 69. Local recurrence of breast cancer in young women – a molecular genetic 72 study of age-related prognostic tumour markers. Tinne Laurberg, MSc Medicine Study visit at BC Cancer Agency, Canada Granted for 2012 - 2013: DKK 41,400 70. Incidence of EML4-AKT gene rearrangement among patients with pulmonary adenocarcinoma. Anders Mellemgaard, PhD, consultant Department of Pathology, Rigshospitalet Granted for 2013: DKK 245,500 *71. Degree of differentiation and genetic and epigenetic profiles of testicular cancer in relation to prognosis: Implications for individual therapy. Ewa Rajpert-De Meyts, MD, PhD Department of Growth and Reproduction, Rigshospitalet Granted for 2012-2014: DKK 1,350,000 *72. Identification and characterisation of circulating exosomes in bladder cancer patients with focus on mRNA and non-coding RNA. Marie Stampe Ostenfeld, MSc, PhD Department of Molecular Medicine (MOMA), Skejby Hospital Granted for 2011-2013: DKK 1,350,000 73. Identification and evaluation of new points of attack for treating patients with glioblastoma multiforme. Hans Skovgaard Poulsen, MD, consultant Radiation Biology Laboratory, Finsen Centre, Rigshospitalet Granted for 2013-2015: DKK 1,500,000 *74. Genetic variability in von Hippel-Lindau disease (vHL). Marie Louise Mølgaard Poulsen, medical student Department of Cellular and Molecular Medicine, University of Copenhagen Granted for 2011-2013: DKK 1,350,000 75. Determination of real-time tumour movement and its application for dynamic tumour tracking during radiation therapy. Per Rugård Poulsen, PhD, physicist, associate professor Department of Oncology, Aarhus University Hospital Granted for 2013-2015: DKK 1,650,000 *76. MicroRNA expression and function in T-cell lymphomas. Professor Elisabeth Ralfkiaer, MD, consultant Department of Pathology, Rigshospitalet Granted for 2012-2014: DKK 1,050,000 *77. Finding alternative splice types and alternative promoters for Acute Myeloid Leukaemia. Albin Sandelin, MSc, PhD, associate professor Bioinformatics Centre, University of Copenhagen Granted for 2011-2013: DKK 1,200,000 78. Oxaliplatin-induced polyneuropathy in patients treated for colorectal cancer. Professor Søren Hein Sindrup, MD, consultant Clinical Institute, Odense University Hospital Granted for 2013-2015: DKK 925,000 79. Three-dimensional dosimetry for future therapy techniques in radiation therapy. Peter Sandegaard Skyt, MSc Department of Oncology, Aarhus University Hospital Granted for 2013-2014: DKK 1,200,000 80. Deregulation of vaults as a possible participant to cancer development: from basic biology to clinical trials. Alexandra Søgaard, MSc Study visit at Norris Comprehensive Cancer Center, University of Southern California, USA Granted for 2012-2013: DKK 48,300 81. Combination of radiation therapy and anti-angiogenesis therapy. Brita Singers Sørensen, MSc, PhD Study visit at BC Cancer Research Centre, Canada Granted for 2012-2013: DKK 61,400 *82. Identification of genetic and epigenetic biomarkers of prostate cancer. Karina Dalsgaard Sørensen, MSc, PhD, associate professor Department of Molecular Medicine, Aarhus Hospital Granted for 2011-2013: DKK 1,800,000 *83. Biomarkers for pancreatic cancer stem cells – towards single-cell cancer diagnostics. Morten Dræby Sørensen, MSc, PhD Centro Nacional de Investigaciones Oncológicas, Spanish National Cancer Research Centre, Spain Granted for 2012-2014: DKK 1,800,000 *84. Cancer invasion and urokinase receptor cleavage – The biomarker potential of the cleaved forms and targeted therapy against the cleavage mechanism. Tine Thurison Sørensen, MSc Finsen Laboratory, Rigshospitalet Granted for 2012-2014: DKK 1,350,000 85. Adoptive T-cell therapy (ATCT) as treatment of malignant haematological disease. Lars Vindeløv, MD, consultant Haematology Clinic, Rigshospitalet Granted for 2013-2015: DKK 1,500,000 Grants *86. New points of attack for the treatment and diagnosis of cutaneous T-cell lymphoma. Professor Niels Feentved Ødum, MD Department of Biology, University of Copenhagen Bevilget for 2010-2013: DKK 2,100,000 *87. Molecular changes in clinical bladder cancer. Professor Torben Falck Ørntoft, MD, consultant Department of Molecular Medicine (MOMA), Skejby Hospital Granted for 2011-2013: DKK 4,300,000 Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements: DKK 17,466,030 * Granted before 2012 and charged to the income statement in previous financial statements. Basic research and epidemiological research 88. Dystrophia myotonica and cancer. Professor Mads Melbye, MD Sector for Epidemiology, Statens Serum Institut Granted for 2013: DKK 650,000 *89. Breast cancer risk from mammographic heterogeneity. Professor Mads Nielsen, MSc, PhD Department of Computer Science, University of Copenhagen Granted for 2012-2014: DKK 1,350,000 *£90.Development of sophisticated statistical methods for examining whether the use of mobile phones increases the risk of brain tumours. Joachim Schüz, MSc, PhD Department of Biostatistics and Epidemiology, Institute of Cancer Epidemiology, Danish Cancer Society Granted for 2011-2013: DKK 1,350,000 *91. Stochastic modelling and analysis of genomic data from heterogeneous tumours, with a particular view to determining tumour age. Professor Carsten Wiuf, MSc, PhD Department of Mathematical Sciences, University of Copenhagen Granted for 2012-2013: DKK 1,200,000 Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements: DKK 650,000 * Granted before 2012 and charged to the income statement in previous financial statements. Basic, clinical and epidemiological research 92. Cryotreatment of renal tumours – correlation between tissue damage and diagnostic imaging presentation. Professor Michael Borre, consultant Department of Urology, Aarhus University Hospital Granted for 2013-2015: DKK 1,500,000 Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements: DKK 1,500,000 * Granted before 2012 and charged to the income statement in previous financial statements. Clinical research 93. Analysis of personal genomic rearrangements (PAGER) for controlling bladder cancer patients. Lars Dyrskjøt Andersen, MSc, PhD, associate professor Department of Clinical Medicine, Skejby Hospital Granted for 2013-2015: DKK 2,100,000 94. Optimising the sentinel node technique for early diagnostics and treatment of lymph node dissemination in melanoma. Annette Hougaard Chakera, MSc Medicine, PhD Study visit at Melanoma Institute Australia Granted for 2013-2014: DKK 99,360 *95. Molecular profiles that are predictive for the effect of long-term antihormone therapy in patients with ER+ breast cancer. Professor Henrik Ditzel, MD, consultant Dept. of Cancer and Inflammation Research, University of Southern Denmark Granted for 2012-2013: DKK 1,400,000 *96. Immunochemotherapy in CLL and MCL for clinical and molecular freedom from disease: The road to a cure? Christian Hartmann Geisler, MD, consultant Finsen Centre, Rigshospitalet Granted for 2011-2013: DKK 1,200,000 97. Nausea and vomiting in advanced cancer: epidemiology, ethiology, significance, effect of guideline-based therapy and two intervention studies. Professor Mogens Grønvold, MD, PhD, consultant Department of Palliative Medicine, Bispebjerg Hospital Granted for 2013-2015: DKK 1,350,000 *98. Very early PET response-adapted therapy of advanced stage Hodgkin lymphoma. Randomised phase III non-inferiority study from the EORTC lymphoma group. Martin Hutchings, PhD, MSc Medicine Oncology and Haematology Clinic, Rigshospitalet Granted for 2012-2016: DKK 250,000 *99. Chronic pain after breast cancer surgery. Professor Henrik Kehlet, MD Breast Surgery Clinic, Rigshospitalet Granted for 2011-2013: DKK 1,350,000 *100. M olecular imaging for non-invasive tumour characteristics and tailored cancer treatment: Translational studies of neuroendocrine tumours. Professor Andreas Kjær, MD, PhD, consultant Cluster for Molecular Imaging/Clinic of Clinical Physiology, Department of Nuclear Medicine & PET, Rigshospitalet Granted for 2011-2013: DKK 3,300,000 101. Chronic pain after rectal cancer therapy. A prospective study. Professor Søren Laurberg, MD, consultant Surgical Department, Aarhus Hospital Granted for 2013-2015: DKK 2,960,000 *102. A phase III trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer - ENGOT-EN2-DGCG. Mansoor Raza Mirza, MSc Medicine, consultant Oncology Clinic, Rigshospitalet Granted for 2012-2014: DKK 2,100,000 103. Prospective, randomised multi-centre study of the value of laparoscopic ultrasound scanning in laparoscopic resection of colorectal cancer patients. Professor Michael Bau Mortensen, PhD, consultant Surgical Department, Odense University Hospital Granted for 2013-2015: DKK 1,035,000 73 Danish Cancer Society | Annual Report 2012 *104. Gastrointestinal toxicity and hepatologic complications of allogeneic stem cell transplantation. Klaus Gottlob Müller, MD, MSc Medicine, consultant Bone Marrow Transplantation Unit, Rigshospitalet Granted for 2012-2014: DKK 1,125,000 109. Improved tumour control and reduced toxicity through the use of image-guided radiation therapy for prostate cancer. Per Munck af Rosenschöld, PhD Study visit at Memorial Sloan-Kettering Cancer Center, USA Granted for 2012: DKK 33,120 *114. Clinical trial of novel strategies for cellular immune therapy for patients with metastatic melanomas. Professor Inge Marie Svane, MSc Medicine, consultant Department of Oncology and Haematology, Herlev Hospital Granted for 2012-2014: DKK 1,800,000 105. Investigator-initiated phase II studies of irinotecan in patients with TOP1 gene amplified metastatic breast cancer – two national DBCG studies. Professor Dorte Lisbet Nielsen, MD Cancer Research Centre, Herlev Hospital Granted for 2013-2015: DKK 2,100,000 *110. Characterisation of subtypes of immune cells for ulcerated melanomas. Henrik Schmidt, MD, consultant doctor, associate professor Cancer Centre, Aarhus Hospital Granted for 2012-2014: DKK 1,650,000 *115. Erlotinib PET scanning and measurement of EGF receptors as predictors of treatment response in pulmonary cancer patients. Boe Sandahl Sørensen, PhD, associate professor Department of Clinical Biochemistry, Aarhus University Hospital Granted for 2012-2013: DKK 900,000 *106. The importance of radiation of the parasternal lymph nodes in women after lymph-node surgery – positive early breast cancer. Birgitte Offersen, PhD, consultant doctor, associate professor Department of Oncology, Aarhus University Hospital Granted for 2012-2013: DKK 600,000 *107. Individualised, biologically adapted radiation therapy. Professor Jens Overgaard, MD, consultant doctor Department of Experimental Clinical Oncology, Aarhus Hospital Granted for 2011-2013: DKK 4,800,000 *108. PET probe-guided selective lymph node staging in women with cervical cancer. Lone Kjeld Petersen, MSc Medicine, PhD, consultant doctor Department of Gynaecology and Obstetrics, Aarhus University Hospital Granted for 2012-2013: DKK 900,000 74 111. Improvement of thiopurine/ methotrexate treatment of acute lymphoblastic leukaemia. Professor Kjeld Schmiegelow, consultant doctor Paediatric Oncology Laboratory, Juliane Marie Centre, Rigshospitalet Granted for 2013-2015: DKK 4,500,000 *112. PEG-asparaginase therapy in NOPHO ALL-2008: Antibody formation, pharmacokinetics, pharmacodynamics and side effects. Henrik Schrøder, MD, consultant doctor Department of Paediatrics, Skejby Hospital Granted for 2011-2013: DKK 1,125,000 *113. Myeloablative allogeneic haematopoietic cell transplantation in Denmark. Risk factors, morbidity, mortality and long-term sequelae. Henrik Sengeløv, MSc Medicine, PhD, consultant doctor Department of Haematology, Rigshospitalet Granted for 2012-2013: DKK 460,000 *116. M R-guided radiation therapy in locally advanced cervical cancer: clinical results of two international multi-centre studies. Kari Tanderup, MSc, PhD, associate professor Department of Oncology, Aarhus Hospital Granted for 2012-2014: DKK 1,350,000 *117. Assessment of monitoring frequency following radical operation in patients with stage II and III colorectal cancer. Peer Anders Wille-Jørgensen, MD, consultant Surgical Department, Bispebjerg Hospital Granted for 2010-2014: DKK 750,000 Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements: DKK 14,177,480 *G ranted before 2012 and charged to the income statement in previous financial statements. Clinical and epidemiological research *118. Epidemiological and clinical differences between Epstein-Barr virus positive and negative Hodgkin’s lymphomas. Henrik Hjalgrim, MSc Medicine, PhD, consultant Department of Epidemiology Research, Statens Serum Institut Granted for 2012-2014: DKK 1,350,000 *119. G enomic profiling of hereditary nonpolyposis colorectal cancer; implications for signalling pathways and phenotype. Professor Mef Nilbert, MD, PhD Clinical Research Centre, Hvidovre University Hospital Granted for 2011–2013: DKK 1,200,000 £120.Endocrine disorders and reproductive disturbances after childhood cancer treatment. Jeanette Falck Winther, MSc Medicine, senior researcher Life after cancer, Danish Cancer Society Research Center Granted for 2013-2015: DKK 1,125,000 Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements: DKK 1,125,000 * Granted before 2012 and charged to the income statement in previous financial statements . Epidemiological research £121.Medicinal products with possible chemopreventive effects and the risk of prostate cancer. Søren Friis, MSc Medicine, senior researcher Statistics, bioinformatics and registers, Danish Cancer Society Research Center Granted for 2013-2015: DKK 1,350,000 Grants 122. Sex hormones and the risk of meningioma and glioma. David Gaist, PhD, consultant doctor, associate research professor Department of Neurology, Odense University Hospital Granted for 2013: DKK 450,000 128. The importance of diagnostic variation in Danish general practice for cancer patient prognoses. Professor Mogens Vestergaard, MSc Medicine, PhD Institute of Public Health, Aarhus University Granted for 2013-2014: DKK 648,000 *123. The significance of hormone therapy for the development and mortality of ovarian, colorectal and endometrial cancer. Lina Steinrud Mørch, MSc Clinic of Gynaecology, Juliane Marie Centre, Rigshospitalet Granted for 2011-2013: DKK 1,800,000 Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements: DKK 2,943,000 * Granted before 2012 and charged to the income statement in previous financial statements. 124. Labour market affiliation after haematological cancer. Professor Claus Vinther Nielsen, MSc Medicine, PhD Institute of Public Health, Aarhus University Granted for 2013-2014: DKK 495,000 *125. Congenital deformities and cancer. Professor Jørn Olsen MD, PhD Department of Epidemiology, Aarhus University Granted for 2011-2013: DKK 1,200,000 *126.Psychosocial strain on patient and partner after breast cancer. An epidemiological investigation. Nina Rottmann, MSc (psychology) Institute of Public Health, University of Southern Denmark Granted for 2012-2013: DKK 900,000 *£127.Cancer among young Danes – survival and heart disease as long-term sequelae. Kathrine Rugbjerg, MSc Genetics and Medicine, Institute of Cancer Epidemiology, Danish Cancer Society Granted for 2012-2013: DKK 1,200,000 KBVU scholarships 129. The significance of B-CLL and HCMV for the functionality of NK cells – focusing on intracellular signalling and degranulation. Christian Buus, medical student Cancer immunology, Department of Biomedicine, Aarhus University Granted for 2012: DKK 110,000 £130.Characterisation of lysomal cystein cathepsin B secretion in ErbB2-induced cell invasion in malignant cancers. Knut Kristoffer Bundgaard Clemmensen, science student Cell death and metabolism, Danish Cancer Society Research Center Granted for 2012: DKK 70,000 131. Is there an optimal timing for starting chemotherapy after primary surgery for ovarian cancer? Lisbeth Lydiksen Christensen, medical student Department of Gynaecology and Obstetrics, Aarhus University Hospital, Skejby Granted for 2012: DKK 120,000 132. The diagnostic and prognostic importance of proliferation markers in sentinel node biopsies for malignant melanomas. Allan Vestergaard Danielsen, medical student Department of Pathology, Aarhus University Hospital Granted for 2012: DKK 120,000 137. A prospective study of diffusionweighted MR diagnostics of hepatic metastases extending from colon cancer – perspectives based on healthcare economics and patient perception. Talie Alsadat Hadi Khadem, medical student Gastrointestinal unit, surgical section, Herlev Hospital Granted for 2012: DKK 110,000 133. Leukocyte DNA-6TgN for monitoring thiopurine-based maintenance treatment in children with leukaemia. Maria Schou Ebbesen, medical student Department of Paediatrics II, Juliane Marie Centre, Rigshospitalet Granted for 2012: DKK 80,000 138. Characterisation of immune-regulating cells in blood from prostate cancer patients. Manja Idorn, science student Centre for Cancer Immunotherapy, Herlev Hospital Granted for 2012: DKK 70,000 134. Optic glioma in children and adolescents with or without neurofibromatosis type 1. Charlotte Ehlers-Hansen, medical student Paediatric Oncology Laboratory, Juliane Marie Centre, Rigshospitalet Granted for 2012: DKK 100,000 139. Cancer vaccination designed for counteracting immune evasion and immunosuppression. Eydbjørg Gaard Joensen, medical student Laboratory for Experimental Vaccinology, University of Copenhagen Granted for 2012: DKK 120,000 135. The role of Akt, Mek, c-Met and PI3K kinase inhibitors in preventing metastasis of tumour cells in the triple-negative breast cancer subtype. Jesper Dupont Ewald, medical student Dept. of Cancer and Inflammation, Institute of Molecular Medicine, University of Southern Denmark Granted for 2012: DKK 120,000 140. Immunoregulation after chemotherapy and stem cell transplant: The significance of interleukin-7 receptor polymorphisms. Katrine Kielsen, medical student Institute for Inflammatory Research, Rigshospitalet Granted for 2012: DKK 120,000 136. Personalised therapy for glioblastoma patients using a new biomarker for chemoresistance. Sofie Hellwege, medical student Department of Clinical Pathology, Odense University Hospital Granted for 2012: DKK 120,000 141. Towards personalised therapy for glioblastoma using multiplexing of biomarkers. Jakob Klitkou, medical student Department of Clinical Pathology, Odense University Hospital Granted for 2012: DKK 120,000 75 Danish Cancer Society | Annual Report 2012 142. Characterisation of SSX2-associated protein complexes and their role in chromatin regulation in cancer cells. Stine Bjørn Kristensen, medical student Dept. of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark Granted for 2012: DKK 110,000 143. Treatment-induced toxicity in children with leukaemia – significance of baseline inflammation level. Ladan Ghulam Mohammad, medical student Institute for Inflammatory Research, Rigshospitalet Granted for 2012: DKK 100,000 144. Characterisation of phenotype and genotype of germ cell tumours in children. Christiane Hammershaimb Mosbech, medical student Department for Growth and Reproduction, Juliane Marie Centre, Rigshospitalet Granted for 2012: DKK 120,000 145. Trend in cervical cancer screening results when implementing new technologies. Johanne Rask Møller, medical student Institute of Public Health, Centre for Epidemiology and Screening, IFSV, University of Copenhagen Granted for 2012: DKK 70,000 146. Retrospective assessment of the quality of treatment response in acute myeloid leukaemia and the effect on the prognosis. Anders Oest, medical student Clinical Research Unit, Department of Haematology, Aalborg Hospital Granted for 2012: DKK 120,000 76 147. Generation and analysis of synthetic breast cancer stem cells. Sidsel Bering Olsen, science student Institute of Molecuar Medicine, University of Southern Denmark Granted for 2012: DKK 60,000 £148.Targeted treatment of tamoxifen- resistant breast cancer cells by inhibiting activated protein kinase signalling pathways. Astrid Munk Pedersen, science student Breast Cancer Group, Danish Cancer Society Research Center Granted for 2012: DKK 60,000 149. Methotrexate polyglutamates in methotrexate/6-mercaptopurine maintenance treatment of acute lymphoblastic leukaemia in children. Tina Gerbek Pedersen, medical student Paediatric Oncology Laboratory, Rigshospitalet Granted for 2012: DKK 120,000 150. Hereditary bowel cancer with unknown genetic background. Laura Aviaja Rudkjøbing, medical student Department of Cellular and Molecular Medicine, University of Copenhagen Granted for 2012: DKK 100,000 151. Surgery and rehabilitation in oral cavity cancer - database for monitoring actions and quality and for facilitating research. Kirstine Rødsten, medical student Plastic Surgery Department, Odense University Hospital Granted for 2012: DKK 120,000 152. A comparison of gene expression profiling of leukemic cells in bone marrow and cerebrospinal fluid, respectively Yagmur Sisman, medical student Department of Paediatrics, Rigshospitalet Granted for 2012: DKK 120,000 153. Identification of DNA methylation biomarkers for a more correct staging of non-small-cell lung cancer patients. Signe Søes, medical student Department of Biomedicine, Aarhus University Granted for 2012: DKK 90,000 154. Chronic inflammation and autoimmunity in myeloid cancer: The Philadelphianegative chronic myeloproliferative neoplasms. Anders Lindholm Sørensen, medical student Haematological Department, Roskilde Hospital Granted for 2012: DKK 120,000 155. PTLD after kidney transplant in Western Denmark and EBV status. Eva Futtrup Sørensen, medical student Department of Nephrology, Aarhus University Hospital, Skejby Granted for 2012: DKK 120,000 156. Do guide marks on the ultrasound transducer have an effect on blood vessel puncture precision? Sofie Thorn, medical student Anaesthesiological-Intensive dept., Iresearch, Aarhus University Hospital, Skejby Granted for 2012: DKK 110,000 157. Is ovarian cancer an infection? – A 16S PCR investigation for bacterial DNA in ascites fluid/tumour tissue in ovarian cancer patients. Julie Mie Tjørring, medical student Department of Gynaecology and Obste trics, Aarhus University Hospital, Skejby Granted for 2012: DKK 100,000 158. Expression of Polycomb and Hox genes in CML patients: A possible marker of a leukemic stem cell? Rikke Tolstrup, medical student Immune-Haematological Laboratory, Aarhus University Hospital Granted for 2012: DKK 120,000 159. Validation of ex vivo culture of human breast cancer cells and the use of this method for assessing sensitivity to BH3 mimetics. Ea Rebekka Vinten, science student Department of Molecular Biology and Genetics, Aarhus University Granted for 2012: DKK 60,000 Granted by KBVU in 2012 and charged to the income statement in the 2012 financial statements: DKK 3,200,000 Grants from the Psychosocial Cancer Research Committee (KPSK) Psychosocial research 160. Preparatory grant: A comparative anthropological study of accelerated patient pathways: Implications for patient roles, relations and organisation. Rikke Aarhus, MA Diagnostics Centre, Regional Hospital Silkeborg Granted for 2013: DKK 56,250 161. When life hurts – a mixed-method study of health, quality of life and resources in 8 to 15-year-olds when a parent suffers from cancer. Anette Hauskov Graungaard, MSc Medicine, PhD, post doc. Research Unit for General Practice, University of Copenhagen Granted for 2013: DKK 221,000 Grants 162. Cognitive changes and existential values and experiences in palliative cancer patients. Niels Viggo Hansen, MA, PhD, centre manager Centre for Research in Existence and Society, University of Copenhagen Granted for 2013: DKK 370,000 167. Daily organisation of psychosocial work and soft relations in accelerated breast cancer: A comparative study. Anne Roelsgaard Obling, MA, PhD, assistant professor Department of Organization, Copenhagen Business School Granted for 2013: DKK 600,000 163. Cancer, body and self images: a visual analysis of Danish autobiographical cancer patient stories. Nina Henriksen, MA, PhD, post doc. Institute of Public Health, University of Southern Denmark Granted for 2013: DKK 600,000 168. Individual support for women in the process after surgical treatment for gynaecological cancer – a randomised intervention study. Professor Bent Ottesen, MD, Centre Director Juliane Marie Centre, Rigshospitalet Granted for 2013: DKK 450,000 164. Establishing a disease narrative after the patient’s first consultation with an oncologist. An analysis of the relation between information, narration and healing. Merete Demant Jakobsen, PhD, post doc. Institute of Public Health, University of Southern Denmark Granted for 2013: DKK 330,000 165. Semi-outpatient treatment of patients with acute leukaemia. Experiences of patients and relatives – illustrated in a rehabilitation perspective. Lene Østergaard Jepsen, MSc Medicine Home-care unit, Odense University Hospital Granted for 2013: DKK 465,000 166. Philosophical dialogue in cancer rehabilitation – cancer counselling in a philosophical perspective. Jeanette Bresson Ladegaard Knox, MPhil, MA Department of Health Services Research, University of Copenhagen Granted for 2013: DKK 488,000 Granted by KPSK in 2012 and charged to the income statement in the 2012 financial statements: DKK 3,580,250 * Granted before 2012 and charged to the income statement in previous financial statements. KPSK preparatory grants 169. Genetic counselling for breast cancer – patient and healthcare professional perspectives. Christina Vigel Mischorr-Boch, MSc (Public Health) Unit for Health Promotion Research, University of Southern Denmark Granted for 2012: DKK 187,500 Granted by KPSK in 2012 and charged to the income statement in the 2012 financial statements: DKK 432,500 for preparatory grants. Research grants from the Danish Cancer Society’s Strategic Committee (KBSU) - (terminated June 2012) Pool for research into social disparity in cancer *171. Socioeconomic status and cancer. Selection or causal effect. Professor Merete Osler, MSc Medicine Department of Social Medicine, Institute of Public Health, University of Copenhagen Granted for 2010-2012: DKK 1,800,000 *172. Social disparity in examination and diagnosis of cancer patients – an analysis of the importance of social factors for the quality of cancer examination and diagnosis and the subsequent survival. Professor Peter Vedsted, MSc Medicine, PhD Research Unit for General Practice, Aarhus University Granted for 2010-2012: DKK 1,600,000 Granted by KBSU in 2009 and charged to the income statement in the financial statements for 2009. Pool for research into long-term sequelae after cancer treatment £170Future organisation of post-treatment follow up – developing and testing a stratification model for the needs of cancer patients. Cecilie Sperling, MSc (Public Health) Quality and Patient Safety, Danish Cancer Society Granted for 2012-2013: DKK 245,000 *174. L ate side effects in patients with testicular cancer related to chemo therapy and hypogonadism. Gedske Daugaard, MD, consultant Oncology Clinic, Rigshospitalet Professor Bobby Zachariae, MD, MSc (Psychology) Psycho-oncological Research Unit, Aarhus Hospital Granted for 2011-2013: DKK 1,000,000 *175. P ost-treatment sequelae after rectal cancer. Professor Søren Laurberg, MD, consultant Surgical Department, Aarhus Hospital Granted for 2010-2013: DKK 2,000,000 Granted by KBSU in 2009 and charged to the income statement in the financial statements for 2009. Pool for palliation research *176. Is access to specialised palliative care distorted and can palliative needs among non-referred cancer patients be met? Mogens Grønvold, MD, PhD, associate professor, consultant Department of Palliative Medicine, Bispebjerg Hospital Granted for 2010-2013: DKK 2,500,000 Granted by KBSU in 2009 and charged to the income statement in the financial statements for 2009. *173. Radiation-induced long-term sequelae: Biological background, prediction and intervention. Jan Alsner, MSc, PhD, associate professor Department of Experimental Clinical Oncology, Aarhus University Granted for 2010-2013: DKK 1,500,000 77 Danish Cancer Society | Annual Report 2012 Pool for “Live Life” – cancer prevention effort *177. Professor Morten Grønbæk, MSc Medicine, MD, PhD Centre for Intervention Research, University of Southern Denmark Granted for 2011-2014: DKK 31,127,821 The grant is awarded in partnership with the Tryg Foundation. Pool for “From Symptom to Treatment” – optimised cancer disease diagnostics *178. Professor Peter Vedsted, PhD Research Centre for Cancer Diagnosis in Primary Care (CaP), Aarhus University Granted for 2010-2014: DKK 15,000,000 The grant is awarded in partnership with the Novo Nordisk Foundation. The pool “Returning to Daily Life” – optimised rehabilitation of cancer patients *179. Professor Lis Adamsen, PhD University Hospitals’ Centre for Nursing and Care Research, Rigshospitalet Granted for 2011-2015: DKK 15,000,000 The grant is awarded in partnership with the Novo Nordisk Foundation. Strategic research initiative on palliation 180. Activity, Cancer and Quality of Life in your own home. Karen la Cour, PhD, associate professor Health, People and Society, Institute of Public Health, University of Southern Denmark 78 Granted for 2012-2017: DKK 3,500,000 The grant is awarded in partnership with the Tryg Foundation. 181. “Fast track” discharge and specialised palliative treatment in the home of the advanced-stage cancer patient: a randomised study. Professor Per Sjøgren, consultant doctor, MD Palliative Section, Unit for acute pain management and palliation, Rigshospitalet Granted for 2012-2017: DKK 5,000,000 The grant is awarded in partnership with the Tryg Foundation. 182. Security in palliative processes. Anders Bonde Jensen, PhD, consultant Mette Asbjørn Neergaard, PhD, staff doctor Palliative Team, Department of Oncology, Aarhus University Hospital Granted for 2012-2016: DKK 4,300,000 The grant is awarded in partnership with the Tryg Foundation. Research professorships *183. Clinical professorship in diagnostics and surgical treatment of gynaecological cancer diseases Professor Jan Blaakær, consultant doctor, MD Department of Clinical Medicine, Aarhus University Granted for 2011-2015: DKK 5,000,000 184. Clinical professorship in surgical application of modern imaging diagnostics Professor Michael Bau Mortensen Surgical Department, Odense University Hospital Granted for 2012-2017: DKK 5,000,000 185. Clinical professorship in palliation Professor Per Sjøgren, consultant doctor, MD Palliative Section, Unit for acute pain management and palliation, Rigshospitalet Granted for 2012-2017: DKK 7,500,000 186. Clinical professorship in cancertreatment sequelae Professor Christoffer Johansen, MD, PhD, consultant Department of Clinical Medicine, Surgery and Internal Medicine, University of Copenhagen Granted for 2013-2018: DKK 7,500,000 187. Clinical professorship in upper gastrointestinal cancer surgery Professor Lars Bo Svendsen, MD, consultant Abdominal Centre, Rigshospitalet Granted for 2012-2017: DKK 1,000,000 Grants General overview 2012 Research grants from the Danish Cancer Society’s Scientific Committee (KVBU) and Psychosocial Cancer Research Committee (KPSK) (DKK 1,000) Granted in 2012 for research projects cf. overview of grants KPSK Basic research Basic and clinical research Basic and epidemiological research Basic, clinical and epidemiological research Clinical research Clinical and epidemiological research Epidemiological research KBVU Total 25,826 17,466 650 1,500 14,177 1,125 2,943 25,826 17,466 650 1,500 14,177 1,125 2,943 Psychosocial research 3,580 Projects, total 3,580 63,687 67,267 Granted to projects, ref. above Granted for preparatory grants Granted for scholarships* Granted for trips under 1 month 3,580 433 63,687 3,200 672 67,267 433 3200 672 Granted, total 4,012 67,559 71,571 -30 -6,790 -1,096 -6,820 -1,096 3,982 59,673 63,655 Adjustment of grants Covered by legacy income Total consumption for the year cf. note 8 in the financial statements 3,580 Comments: 1. Postdoc and junior bursaries have been included under project grants. 2.The breakdown by specialist discipline has been based on the applicant ticking one or more of the following headings: basic research, clinical research, epidemiology, psychosocial research and other. * Incl. the Employers' Reimbursement Scheme (Apprentices and Trainees) (AER) 79 Danish Cancer Society | Annual Report 2012 Patients’ associations Danish Ostomy Association - COPA The Patients’ Association DBO Chairman: Henning Granslev Secretariat Jyllandsgade 41 DK-4100 Ringsted Tel.: (+45) 57 67 35 25 [email protected] (Contact at FAP, special subgroup: Susanne Jacobsen [email protected] (Danish Breast Cancer Organisation) Skivevej 150 DK-9632 Møldrup Tel. (+45) 26 82 39 29 [email protected] Chairman: Helle Viola Haugaard [email protected] DALYFO Ole Dallris Scaniagade 14 DK-8900 Randers Tel. (+45) 86 40 80 62 [email protected] Danish Lymphoedema Association Lise Petersen Arent Hansens Vej 3, Smidstrup DK-3250 Gilleleje Tel. (+45) 70 22 22 10 [email protected] Danish Association for Laryngectomees – DLFL Anne-Lise Steen Lindormevej 14, Kulhuse DK-3630 Jægerspris Tel. (+45) 47 53 63 30 [email protected] Office Strandboulevarden 49, 4. DK-2100 Copenhagen Ø Tel. (+45) 35 25 74 24 / (+45) 35 26 40 45 [email protected] 80 Danish Myeloma Association KIU – Women with reproductive cancers Lene Middelhede Rosenvænget 5A DK-8722 Hedensted Tel. (+45) 76 74 05 44 / (+45) 51 70 87 83 [email protected] PROPA Danish Prostate Cancer Association K. B. Madsen, Baldersvej 19 DK-4000 Roskilde Tel. (+45) 46 37 11 09 / (+45) 40 13 15 47 [email protected] Secretariat: Danish Prostate Cancer Association PROPA Jernbanegade 23 B DK-4000 Roskilde Tel. (+45) 33 12 78 28 [email protected] Danish Association for Children with Cancer Jan Johnsen Karlslunde Strandvej 56 DK-2690 Karlslunde Tel. (+45) 20 30 09 05 [email protected] Danish Lung Cancer Association Alice Skjold Braae Virkelyst 1 DK-4420 Regstrup Tel. (+45) 40 16 23 35 [email protected] Danish Bladder Cancer Association Danish Brain Tumour Association The Association Netpa Denmark Bitten Næsted Jægersborg Allé 29B 2. tv. DK-2920 Charlottenlund [email protected] Marbækvej 8 DK-4050 Skibby [email protected] Danish Association of Cancer Survivors with Late Effects – Late Effects Group Networks Marianne Nord Hansen Bringebakken 30, DK-3500 Værløse [email protected] Cancer Counselling Centre in Lyngby Nørgaardsvej 10 DK-2800 Lyngby (+45) 45 93 51 51 [email protected] Proof of Life Christian Hajdu [email protected] [email protected] Børge Tamsmark Hostrups Have 30 5 tv. DK-1954 Frederiksberg C Tel. (+45) 25 86 92 74 [email protected] Melanoma network LyLe - Danish Patients’ Association for Lymphatic Cancer and Leukaemia Ryesgade 27 DK-2200 Copenhagen N Tel. (+45) 35 27 18 00 Jytte Gamby Lundemosen 78 DK-2670 Greve Tel. (+45) 43 90 54 50 [email protected] [email protected] Health centre for cancer patients, Counselling unit Network for patients with cancer of the throat and oral cavity Bodil Feldinger, Tel. (+45) 45 83 45 27 Niels Jessen, Tel. (+45) 48 17 59 64 c/o Centre for Cancer and Health Nørre Alle 45 DK-2200 Copenhagen N [email protected] Intestinal cancer patient network Annelise Læssøe Marianne de Fries Jensen Jørgen Mathiesen Kirsten Andersen [email protected] Postal address only: Annelise Læssøe Mariendalsvej 63B, 3.th. DK-2000 Frederiksberg Drivkræften - network for young people with cancer Contact person: Tina Brændgaard Tel. (+45) 35 25 74 76 [email protected] IMPORTANT CONTACT DETAILS Cancer Counselling Centres Nation-wide Cancer line The Danish Cancer Society’s free telephone counselling Tel.: +45 80 30 10 30 Opening hours: Mondays-Fridays 9 am – 9 pm Saturdays and Sundays noon – 5 pm Closed on public holidays The Capital Region of Denmark The cancer counselling centre Møllestræde 6 Baghuset DK-3400 Hillerød Tel. (+45) 48 22 02 82 [email protected] The cancer counselling centre Centre for Cancer and Health Nørre Allé 45 DK-2200 Copenhagen N Tel. (+45) 82 20 58 05 [email protected] The cancer counselling centre Bornholm Hospital Ullasvej 8 DK-3700 Rønne Tel. (+45) 56 90 91 98 The cancer counselling centre Nørgaardsvej 10 DK-2800 Lyngby Tel. (+45) 45 93 51 51 [email protected] Region Zealand The cancer counselling centre Hasselvænget 5 DK-4300 Holbæk Tel. (+45) 59 44 12 22 [email protected] The cancer counselling centre Ringstedgade 71 DK-4700 Næstved Tel. (+45) 70 20 26 46 [email protected] The cancer counselling centre Jernbanegade 16 DK-4000 Roskilde Tel. (+45) 46 30 46 60 [email protected] The cancer counselling centre Volunteer Centre Lolland Sdr. Boulevard 84, stuen DK-4930 Maribo Tel. (+45) 55 74 04 00 The cancer counselling centre Søndre Allé 43 B DK-4600 Køge Tel. (+45) 56 63 82 29 Network café for cancer patients and relatives Guldborgsund Frivilligcenter Banegårdspladsen 1A, DK-4800 Nykøbing F Tel. (+45) 70 20 26 46 The cancer counselling centre Nykøbing F. Hospital Ejegodvej 67 (bus 701) DK-4800 Nykøbing F Tel. (+45) 70 20 26 46 By appointment only Cancer counselling at the Info Shop Lindegade 3 DK-4400 Kalundborg Tel. (+45) 59 44 12 22 Cancer counselling at Health Centre Odsherred Sygehusvej 5, 1. th DK-4500 Nykøbing Sj. [email protected] Appointments and information on tel. (+45) 59 41 01 10 North Denmark Region The cancer counselling centre Vesterå 5 DK-9000 Aalborg Tel. (+45) 98 10 92 11 [email protected] New address from 26 August: Stenstrupvej 1 DK-9000 Aalborg Cancer counselling at the Health Centre Banegårdspladsen, 5, 2. sal DK-9800 Hjørring Tel. (+45) 98 10 92 11 First Monday of every month 9 am – 3 pm Cancer counselling at Dragsbækcentret Simons Bække 37, Tilsted DK-7700 Thisted Information about opening hours on tel. (+45) 98 10 92 11 Central Denmark Region The cancer counselling centre Overgade 17 DK-7400 Herning Tel. (+45) 96 26 31 60 [email protected] The cancer counselling centre Banegårdspladsen 2. 1. DK-8800 Viborg Tel. (+45) 86 60 19 18 [email protected] Hejmdal – The Cancer Patients' House Peter Sabroes Gade 1 DK-8000 Århus C Tel. (+45) 86 19 88 11 [email protected] Cancer counselling at Health Centre West Kirkegade 3 DK-6880 Tarm Tel. (+45) 96 26 31 60 [email protected] REGION OF SOUTHERN DENMARK The cancer counselling centre Jyllandsgade 30 DK-6700 Esbjerg Tel. (+45) 76 11 40 40 [email protected] The cancer counselling centre Kulturhuset Nygade 22 DK-7500 Holstebro Tel. (+45) 96 26 31 60 [email protected] The cancer counselling centre Vesterbro 46 DK-5000 Odense C Tel. (+45) 66 11 32 00 [email protected] Cancer counselling at the Health Centre Sygehusvej 7 DK-8660 Skanderborg Tel. (+45) 86 19 88 11 By appointment only Cancer counselling at Randers Health Centre Biografgade 3 DK-8900 Randers C Tel. (+45) 89 15 12 15 Open Mondays 10 am – 3 pm Cancer counselling at the Health Centre Østergade 9, 1. sal DK-8600 Silkeborg Tel. (+45) 86 19 88 11 [email protected] Cancer counselling at Odder Volunteer Centre Pakhuset Banegårdsgade 5 DK-8300 Odder Tel. (+45) 86 19 88 11 [email protected] The cancer counselling centre Blegbanken 3 DK-7100 Vejle Tel. (+45) 76 40 85 90 [email protected] The cancer counselling centre Nørreport 4, 1. DK-6200 Aabenraa Tel. (+45) 74 62 51 50 [email protected] Volunteer counselling service Svendborg Brogade 35 (i gården) DK-5700 Svendborg Tel. (+45) 23 98 06 95 Open Tuesdays 10 am – noon and Thursdays 5 pm – 7 pm Volunteer counselling service – The Prevention Centre Fredensvej 1 DK-5900 Rudkøbing Tel. (+45) 62 51 28 90 Open Wednesdays 2 pm - 4 pm Kolding cancer counselling Klostergade 16 DK-6000 Kolding Tel. (+45) 79 79 72 80 Open Mondays 9 am - 1 pm By appointment only. 81 Danish Cancer Society | Annual Report 2012 82 Organisation Local units Committee of Representatives Presidium Central Board Regional Committees Executive Committee Local Units Committee The Danish Cancer Society’s Scientific Committee Patient Support Committee The Danish Cancer Society’s Strategic Committee Prevention and Information Committee Psychosocial Research Committee Management Policy and Legal Advice Communications Department HR Finances & Administration Volunteering Fundraising & Membership Patient Support & Community Activities Cancer Prevention & Documentation Quality & Patient Safety The Danish Cancer Society Research Center 83 The Annual Report can be ordered from the Danish Cancer Society by calling (+45) 3525 7540 or downloaded from www.cancer.dk/regnskaber The English version is available at www.cancer.dk/regnskaber Danish Cancer Society Strandboulevarden 49 DK-2100 Copenhagen Tel. + (45) 35 25 75 00 www.cancer.dk CVR 55 62 90 13